UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

KBC ASSET MANAGEMENT NV, et al., Individually and on Behalf of All Others Similarly Situated, Plaintiff, vs. AEGERION PHARMACEUTICALS, INC., et al., Defendants.	No. 1:14-cv-10105-MLW CLASS ACTION DECLARATION OF CAROLE K. SYLVESTER REGARDING NOTICE DISSEMINATION, PUBLICATION, AND REQUESTS FOR EXCLUSION RECEIVED TO DATE

I, CAROLE K. SYLVESTER, declare:

1. I am employed as the Director of Notice by Gilardi & Co. LLC ("Gilardi"), located at 3301 Kerner Blvd., San Rafael, California. The Court's Order Preliminarily Approving Settlement and Providing for Notice, dated June 29, 2017 (Dkt. No. 145-1) (the "Notice Order"), appointed Gilardi to serve as the Claims Administrator in connection with the proposed settlement of the above-captioned litigation (the "Litigation"). I oversaw the notice services that Gilardi provided in accordance with the Notice Order.

2. I submit this declaration in order to provide the Court and the parties to the Litigation with information regarding the: (i) mailing of the Court-approved Notice of Proposed Settlement of Class Action (the "Notice") and the Proof of Claim and Release (the "Proof of Claim") (together, the "Notice Package"), (ii) posting of those and other documents on the website created for and dedicated to the Litigation, (iii) publication of the Summary Notice, and (iv) number of requests for exclusion from the Class received by Gilardi to date.

3. I am over 21 years of age and am not a party to this Litigation. I have personal knowledge of the facts set forth herein and, if called as a witness, could and would testify competently thereto.

DISSEMINATION OF THE NOTICE PACKAGE

4. Pursuant to the Notice Order, Gilardi is responsible for disseminating the Notice Package to potential Class Members. By definition, Class Members are Persons who purchased or otherwise acquired Aegerion Pharmaceuticals, Inc. ("Aegerion") publicly traded common stock between April 30, 2013 and May 11, 2016, inclusive (unless otherwise excluded). True and correct copies of the Notice and Proof of Claim are attached hereto as Exhibits A and B, respectively.

5. Gilardi obtained from the transfer agent for Aegerion a list containing the names and addresses of potential Class Members. The list was reviewed to identify and eliminate duplicate

entries and incomplete data, resulting in a usable mailing list of seven unique names and addresses. Gilardi had the unique name and address data printed on to Notice Packages, posted the Notice Packages for First-Class Mail prepaid, and delivered seven Notice Packages on July 20, 2017, to the United States Post Office located in Santa Rosa, California.

6. In addition, on July 20, 2017, as part of its normal mailing procedures, Gilardi mailed, by First-Class Mail, Notice Packages and cover letters to 279 brokerages, custodial banks, and other institutions ("Nominal Holders") that hold securities in "street name" as nominees for the benefit of their customers who are the beneficial owners of the securities. The Nominal Holders also include a group of filers/institutions who have requested notification of every securities case. These Nominal Holders are included in a proprietary database created and maintained by Gilardi. In Gilardi's experience, the Nominal Holders included in this proprietary database represent a significant majority of the beneficial holders of securities. The cover letter accompanying the Notice Packages advised the Nominal Holders of the proposed settlement and requested their cooperation in forwarding the Notice Packages to potential Class Members. In the over 25 years that Gilardi has been providing notice and claim administration services in securities class actions, Gilardi has found the majority of potential class members hold their securities in street name and are notified through the Nominal Holders. Gilardi also mailed Notice Packages and cover letters to the 4,668 institutions included on the U.S. Securities and Exchange Commission's ("SEC") list of active brokers and dealers at the time of mailing. A sample of the cover letter mailed to Nominal Holders and the institutions included on the SEC's list of active brokers and dealers is attached hereto as Exhibit C.

7. On July 20, 2017, Gilardi also delivered electronic copies of the Notice Package to 408 registered electronic filers who are qualified to submit electronic claims. These filers are primarily

institutions and third-party filers who typically file numerous claims on behalf of beneficial owners for whom they act as trustees or fiduciaries.

8. As part of the notice program for this settlement, Gilardi also caused the Notice Package to be published by the Depository Trust Company ("DTC") on the DTC Legal Notice System ("LENS"). LENS enables the participating bank and broker nominees to review the Notice Package and contact Gilardi for copies of the Notice Package for their beneficial holders.

9. Gilardi has acted as a repository for shareholder and nominee inquiries and communications received in this Litigation. In this regard, Gilardi has forwarded the Notice Package on request to nominees who purchased or acquired the publicly traded common stock of Aegerion for the beneficial interest of other persons. Gilardi has also forwarded the Notice Package directly to beneficial owners upon receipt of the names and addresses from such beneficial owners or nominees.

10. Following the initial mailing, Gilardi received 26 responses to the outreach efforts described above, including computer files containing a total of 27,224 names and addresses of potential Class Members. Gilardi has also received three responses that included mailing labels with names and addresses of an additional 269 potential Class Members. In addition, 13 institutions requested that Gilardi send them a total of 25,610 Notice Packages for forwarding directly to their clients. Each of these requests has been completed in a timely manner.

11. As of the date of this declaration, Gilardi has mailed a total of 58,465 Notice Packages to potential Class Members and nominees.

TELEPHONE HOTLINE AND WEBSITE

12. Gilardi established and continues to maintain a toll-free telephone number to accommodate potential Class Member inquiries. This toll-free number, 1-844-319-2120, became operational on July 20, 2017. The toll-free telephone number was set forth in the Notice, Summary

Notice, and on the case website. All inquiries to the toll-free telephone number have been and will continue to be promptly responded to.

13. To further assist potential Class Members in connection with the settlement, Gilardi established and maintains a website dedicated to the settlement (www.aegerionsecuritieslitigation.com). The web address was set forth in the Notice Package and Summary Notice. This website became operational on July 14, 2017. On that date, and since, visitors to the website could download a copy of the Stipulation of Settlement, the Complaint, and the Notice Order, among other relevant documents. On July 20, 2017, the Notice and Proof of Claim were added to the website. Class Members can also complete and submit a Proof of Claim through the website.

PUBLICATION OF THE SUMMARY NOTICE

14. In accordance with the Notice Order, Gilardi caused the Summary Notice to be published in *The Wall Street Journal* and transmitted over the *Business Wire* on July 25, 2017, as shown in the Declarations of Publication attached hereto as Exhibit D.

REPORT ON EXCLUSION REQUESTS RECEIVED TO DATE

15. The Notice informs potential Class Members that written requests for exclusion from the Class must be mailed to *Aegerion Securities Litigation*, Claims Administrator, c/o Gilardi & Co. LLC, EXCLUSIONS, 3301 Kerner Blvd., San Rafael, CA 94901, such that they are postmarked no later than October 31, 2017. The Notice also sets forth the information that must be included in each request for exclusion. Gilardi has monitored and will continue to monitor all mail delivered to this address. As of the date of this declaration, Gilardi has received one request for exclusion, which is attached hereto as Exhibit E.

I declare under penalty of perjury that the foregoing is true and correct. Executed this 29th day of September, 2017, at San Rafael, California.

Carole K. Sylvester

CAROLE K. SYLVESTER

CERTIFICATE OF SERVICE

I hereby certify that this document filed through the ECF system will be sent electronically on this 2nd day of October, 2017, to the registered participants as listed on the Notice of Electronic Filing (NEF). At this time, I am not aware of any non-registered participants to whom paper copies must be sent.

/s/ *Gregg S. Levin*
Gregg S. Levin
MOTLEY RICE LLC

EXHIBIT A

Dear Recipient:

You have been identified as a potential class member in a securities class action involving Aegerion Pharmaceuticals, Inc. captioned *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 1:14-cv-10105-MLW. Enclosed is a notice about the settlement of that class action lawsuit. You may be eligible to claim a payment from the settlement or you may want to act on other legal rights. Important facts are highlighted below and explained in the notice:

- **Security:** Aegerion Pharmaceuticals, Inc. common stock.
- **Time Period:** Aegerion Pharmaceuticals, Inc. stock bought from April 30, 2013 through and including May 11, 2016.
- **Settlement Amount:** $22.25 million (the average distribution will be $0.31 per share if claims are submitted for each share, before deductions for costs and attorneys' fees).
- **Reasons for Settlement:** Avoids costs and risks from continuing the lawsuit; avoids risks resulting from the present weak financial condition of Aegerion and the limited resources with which a settlement or judgment could be paid; releases defendants from liability.
- **If the Case had not Settled:** There would have been further litigation and possibly a trial. Plaintiffs estimated that they may have obtained a judgment as high as $844.6 million, but acknowledge they may not have been able to collect on that judgment. The defendants think that plaintiffs would not have won anything from a trial.
- **Attorneys' Fees and Expenses:** Counsel for the Class will ask the Court for an award of attorneys' fees of 25% of the Settlement Amount, plus expenses not to exceed $250,000. Each of the Class Representatives will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately $0.08 per share of Aegerion common stock included in the Class Period.
- **Deadlines:**
  - **Claims:** November 17, 2017
  - **Exclusions:** October 31, 2017
  - **Objections:** October 31, 2017
  - **Court Hearing on Fairness of Settlement:** November 30, 2017, at 2:00 p.m. ET
- **More Information:** You may contact the Claims Administrator toll-free at 1-844-319-2120, or visit www.aegerionsecuritieslitigation.com. You may also contact representatives of counsel for the Class:

Rick Nelson, Shareholder Relations
Robbins Geller Rudman & Dowd LLP
655 West Broadway, Suite 1900
San Diego, CA 92101
1-800-449-4900

Gregg S. Levin, Christopher F. Moriarty
Motley Rice LLC
28 Bridgeside Blvd.
Mt. Pleasant, SC 29464
1-843-216-9000

Get more details in the enclosed Notice from the United States District Court for the District of Massachusetts.

TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF AEGERION PHARMACEUTICALS, INC. ("AEGERION" OR THE "COMPANY") DURING THE PERIOD FROM APRIL 30, 2013 THROUGH AND INCLUDING MAY 11, 2016 (THE "CLASS PERIOD")

A FEDERAL COURT AUTHORIZED THIS NOTICE. THIS IS NOT A SOLICITATION FROM A LAWYER.

THE COURT HAS RETAINED THE DISCRETION TO ALTER ANY OF THE DEADLINES AND REQUIREMENTS SET FORTH HEREIN FOR GOOD CAUSE SHOWN.

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS ACTION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THE SETTLEMENT PROCEEDS, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE FORM ("PROOF OF CLAIM") **POSTMARKED (IF MAILED) OR RECEIVED (IF SUBMITTED ONLINE) ON OR BEFORE NOVEMBER 17, 2017.**

The purpose of this Notice is to inform you of (i) the pendency of this class action (the "Litigation") between Lead Plaintiffs KBC Asset Management NV, Sheet Metal Workers' National Pension Fund, and Chester County Employees' Retirement Fund ("Lead Plaintiffs") and Defendants Aegerion, Marc D. Beer, Craig Fraser, and Mark J. Fitzpatrick ("Defendants"); (ii) the proposed $22.25 million settlement reached therein (the "Settlement"); and (iii) the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and Lead Counsel's application for fees, costs, and expenses (which will include Lead Plaintiffs' reimbursement for their time and expenses representing the Class). This Notice describes what steps you may take in relation to the Settlement and this class action.[1]

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A PROOF OF CLAIM FORM	The only way to be eligible to receive a payment from the Settlement. Unless otherwise extended by the Court, **Proof of Claim forms must be postmarked (if mailed) or received (if submitted online) on or before November 17, 2017.**
EXCLUDE YOURSELF	Get no payment. This is the only option that ***potentially*** allows you to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement. Unless otherwise extended by the Court, **exclusions must be postmarked on or before October 31, 2017.**
OBJECT	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys' fees and expenses. You will still be a Member of the Class. Unless otherwise extended by the Court, **objections must be *received* by the Court and counsel for the Settling Parties on or before October 31, 2017.**
GO TO THE HEARING ON NOVEMBER 30, 2017 AT 2:00 P.M. ET	Ask to speak in Court about the fairness of the Settlement. Unless otherwise extended by the Court, **requests to speak must be *received* by the Court and counsel for the Settling Parties on or before October 31, 2017.**
DO NOTHING	Receive no payment. You will, however, still be a Member of the Class, which means that you give up your right to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement and you will be bound by any judgments or orders entered by the Court in the Litigation.

SUMMARY OF THIS NOTICE

The Nature of this Lawsuit

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the "Court"). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and omissions of information necessary for investors to understand that JUXTAPID was not performing and could not

[1] All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation of Settlement dated January 17, 2017 (the "Stipulation"), which is available on the website www.aegerionsecuritieslitigation.com.

lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

Statement of Class Recovery

Pursuant to the Settlement described herein, a $22.25 million settlement fund has been established. Based on Lead Plaintiffs' estimate of the number of shares of Aegerion common stock damaged during the Class Period, the average distribution per share under the Plan of Allocation is roughly $0.31 per share before deduction of any taxes on the income earned on the Settlement Amount, notice and administration costs, and allowable attorneys' fees and expenses as determined by the Court. **These are only estimates, however.** A Class Member's actual recovery will be a proportion of the Net Settlement Fund determined by that claimant's claims as compared to the total claims of all Class Members who submit acceptable Proofs of Claim. An individual Class Member may receive more or less than this estimated average amount, depending on the number of claims submitted, when during the Class Period a Class Member purchased or acquired Aegerion common stock, the purchase price paid, and whether those shares were held at the end of the Class Period or sold during the Class Period, and, if sold, when they were sold and the amount received. *See* Plan of Allocation set forth and discussed at pages 9-11 below for more information on the calculation of your claim.

Statement of Potential Outcome of Case

The Settling Parties disagree on both liability and damages and do not agree on the amount of damages that would be recoverable if the Class prevailed on each claim alleged. Defendants deny that they are liable to the Class and deny that the Class has suffered any damages. The issues on which the parties disagree are many, but include: (1) whether Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws, or any other laws; (2) whether Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (4) the amount, if any, by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (5) the effect of various market forces on the price of Aegerion common stock at various times during the Class Period; (6) the extent to which external factors influenced the price of Aegerion common stock at various times during the Class Period; (7) the extent to which the various matters that Lead Plaintiffs alleged were materially false or misleading influenced (if at all) the price of Aegerion common stock at various times during the Class Period; and (8) the extent to which the various allegedly adverse material facts that Lead Plaintiffs alleged were omitted influenced (if at all) the price of Aegerion common stock at various times during the Class Period. A consultant retained by counsel for Plaintiffs has opined that, if Lead Plaintiffs prevailed on all of their claims, recoverable damages could be as high as $844.6 million, an amount which Defendants dispute.

Reasons for the Settlement

Lead Plaintiffs' principal reason for entering into the Settlement is the benefit to the Class now, without further risk or the delays inherent in continued litigation. The cash benefit under the Settlement must be considered against the significant risk that a smaller recovery – or, indeed, no recovery at all – might be achieved after contested motions, trial, and likely appeals, a process that could last several years into the future. Those risks include the present financial condition of Aegerion, the limited insurance proceeds, the resources of the Individual Defendants, and Aegerion's financial obligations under its Settlement Agreement with the U.S. Department of Justice and the U.S. Securities and Exchange Commission. Lead Plaintiffs have therefore concluded that the proposed Settlement is fair, reasonable and adequate to Members of the Class. On November 29, 2016, Aegerion and QLT Inc. ("QLT") merged, with Aegerion becoming an indirect wholly owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc. ("Novelion"). Under the terms of the merger, however, Novelion is not responsible for any liability of Defendants to the Class, and the Class cannot access any of Novelion's assets.

Moreover, at the time of entering into the Settlement, Aegerion's prospects for continuing as a going concern were questioned by its outsider auditor, Ernst & Young LLP ("E&Y"). *See* Aegerion Pharms., Inc., Quarterly Report (Form 10-Q) (Aug. 9, 2016) at 96 (noting E&Y's "substantial doubt" about Aegerion's ability to continue as a going concern in its report for year-end 2015). If Aegerion were to enter bankruptcy, the Class would only have a remote chance of eventually obtaining any recovery. In this regard, from December 31, 2015 to June 30, 2016, Aegerion's available cash fell from $64 million to $46 million. *Id.* at 4. Aegerion's financial situation was such that it needed to arrange a $15 million "lifeline" loan with QLT. Absent such a loan, Aegerion stated that it "would need to raise capital or obtain alternative financing to . . . fund our operations," or it would be forced to "delay, reduce or cease operations." *Id.* at 109. Aegerion also projected that it would have a negative net income of $130 million in 2016 and a negative net income of $53 million in 2017. *See* QLT Inc., Registration Statement (Form S-4) (Aug. 8, 2016) at 80.

Further depleting the available resources available to the Class, Aegerion carries substantial debts and obligations, including $325 million in convertible notes that come due in 2019 and $40 million payable over three years

to the U.S. Department of Justice and the U.S. Securities and Exchange Commission as part of the resolution of certain investigations that had been conducted by those agencies.

Finally, the insurance proceeds available to cover the claims in this Litigation are limited, further reducing the amount available to the Class. The longer the litigation continued, the more the available insurance proceeds would have been reduced, including the possibility that all available insurance policies would have been exhausted before any verdict or later settlement.

For Defendants, who have denied and continue to deny all allegations of liability, fault, or wrongdoing whatsoever in connection with this matter, the principal reason for entering into the Settlement is to eliminate the uncertainty, risk, costs, and burdens inherent in any litigation, especially in complex cases such as this action. Defendants have concluded that further litigation could be protracted and distracting.

Under these circumstances, and given the complex and highly uncertain nature of proceeding with the action and eventually trying this case before a jury, Lead Plaintiffs submit that the resolution of the Litigation for $22,250,000 is an excellent result for the Class.

Statement of Attorneys' Fees and Expenses Sought

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount, plus expenses not to exceed $250,000, plus interest earned on both amounts at the same rate as earned by the Settlement Fund. Since the Litigation's inception, Lead Plaintiffs' Counsel have expended considerable time and effort in the prosecution of this Litigation on a wholly contingent basis and have advanced the expenses of the Litigation in the expectation that if they were successful in obtaining a recovery for the Class, they would be paid from such recovery. In addition, as part of that application, each of the Lead Plaintiffs will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately $0.08 per allegedly damaged share of Aegerion common stock.

Further Information

For further information regarding the Litigation, this Notice or to review the Stipulation, please contact the Claims Administrator toll-free at 1-844-319-2120, or visit the website www.aegerionsecuritieslitigation.com. Additionally, documents related to the Settlement and this case will be posted on the website.

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, www.rgrdlaw.com or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

Please Do Not Call the Court or Defendants with Questions About the Settlement.

BASIC INFORMATION

1. Why did I get this notice package?

This Notice was sent to you pursuant to an Order of a U.S. Federal Court because you or someone in your family or an investment account for which you serve as custodian may have purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016 ("Class Period").

This Notice explains the class action lawsuit, the Settlement, Class Members' legal rights in connection with the Settlement, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of the Litigation is the United States District Court for the District of Massachusetts, and the case is known as *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, Case No. 1:14-cv-10105-MLW. The case has been assigned to the Honorable Mark L. Wolf. The parties representing the Class are the "Lead Plaintiffs," and the company and individuals they sued and who have now settled are called the Defendants.

2. What is this lawsuit about?

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the "Court"). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and

omissions of information necessary for investors to understand that JUXTAPID was not performing and could not lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

On June 1, 2015, Lead Plaintiffs filed their Amended Class Action Complaint ("Amended Complaint"). On July 31, 2015, Defendants filed their Motion to Dismiss the Amended Complaint. On August 21, 2015, Lead Plaintiffs filed their Second Amended Class Action Complaint ("Second Amended Complaint"). Defendants, on September 4, 2015, moved to strike the Second Amended Complaint. Lead Plaintiffs filed their opposition to the Motion to Strike on September 18, 2015.

Following oral argument on Defendants' Motion to Strike the Second Amended Complaint and Lead Plaintiffs' Motion for Leave to File the Second Amended Complaint, the Court entered an order requiring the parties to, among other things, confer and "report whether they have reached an agreement to permit or withdraw the lead plaintiffs' Second Amended Complaint." The parties thereafter conferred but were unable to reach an agreement, and informed the Court that Lead Plaintiffs would file an opposition to the Motion to Dismiss the Amended Complaint.

Following Aegerion's May 12, 2016 announcement that it had reached preliminary agreements in principle with the U.S. Department of Justice and the staff of the U.S. Securities and Exchange Commission regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID, the parties conferred and reached an agreement for Lead Plaintiffs to file their Third Amended Class Action Complaint ("Third Amended Complaint"), which would extend the putative Class Period to April 30, 2013 through May 11, 2016, inclusive. Lead Plaintiffs filed the Third Amended Complaint on June 27, 2016.

In an effort to conserve judicial recovery and attempt to settle the Litigation, the parties engaged the services of the Hon. Daniel Weinstein (Ret.) and Jed Melnick, Esq. of JAMS, nationally recognized mediators. The parties prepared detailed mediation statements and engaged in a full-day in-person mediation session on November 14, 2016. These efforts culminated with the parties agreeing on November 29, 2016, to settle the Litigation for $22,250,000, subject to the negotiation of the terms of a Stipulation of Settlement and approval by the Court.

3. Why is there a settlement?

The Court has not decided in favor of Defendants or in favor of Lead Plaintiffs. Instead, both sides agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and Lead Plaintiffs agreed to the Settlement in order to ensure that Class Members will receive compensation, particularly in light of Aegerion's precarious financial condition and the limited resources of the Defendants.

WHO IS IN THE SETTLEMENT

4. How do I know if I am a Member of the Class?

The Court directed that everyone who fits this description is a Class Member: ***all Persons who purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016***, except those Persons and entities that are excluded.

Excluded from the Class are: Defendants, the officers and directors of Aegerion during the Class Period, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which Defendants have or had a controlling interest. Also excluded from the Class is any Class Member who timely and validly excludes themselves therefrom by submitting a request for exclusion in accordance with the requirements set forth in question 11 below.

Please Note: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive a payment from the Settlement. If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit the Proof of Claim that is being distributed with this Notice and the required supporting documentation as set forth therein postmarked or submitted online on or before November 17, 2017.

5. What if I am still not sure if I am included?

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at 1-844-319-2120, or you can fill out and return the Proof of Claim form enclosed with this Notice package, to see if you qualify.

THE SETTLEMENT BENEFITS – WHAT YOU GET

6. What does the Settlement provide?

The Settlement provides that, in exchange for the release of the Released Claims (defined below) and dismissal of the Litigation, Defendants have agreed to pay (or cause to be paid) $22.25 million in cash to be distributed

after taxes, fees, and expenses, *pro rata*, to Class Members who send in or submit a valid Proof of Claim form pursuant to the Court-approved Plan of Allocation. The Plan of Allocation is described in more detail at the end of this Notice.

7. How much will my payment be?

Your share of the Net Settlement Fund will depend on several things, including the total amount of claims represented by the valid Proof of Claim forms that Class Members send in or submit, compared to the amount of your claim, all as calculated under the Plan of Allocation discussed below.

HOW YOU GET A PAYMENT – SUBMITTING A CLAIM FORM

8. How can I get a payment?

To be eligible to receive a payment from the Settlement, you must submit a Proof of Claim form. A Proof of Claim form is enclosed with this Notice or it may be downloaded at www.aegerionsecuritieslitigation.com. Read the instructions carefully, fill out the Proof of Claim, include all the documents the form asks for, sign it, and **mail or submit it online so that it is postmarked (if mailed) or received (if submitted online) no later than November 17, 2017.** The Proof of Claim form may be submitted online at www.aegerionsecuritieslitigation.com.

9. When would I get my payment?

The Court will hold a Settlement Hearing on November 30, 2017, at 2:00 p.m. ET, to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals. It is always uncertain whether appeals can be resolved, and if so, how long it would take to resolve them. It also takes time for all the Proofs of Claim to be processed. Please be patient.

10. What am I giving up to get a payment or to stay in the Class?

Unless you timely and validly exclude yourself, you are staying in the Class, and that means you cannot sue, continue to sue, or be part of any other lawsuit against Defendants or their Related Parties about the Released Claims (as defined below) in this case. It also means that all of the Court's orders will apply to you and legally bind you. If you remain a Class Member, and if the Settlement is approved, you will give up all "Released Claims" (as defined below), including "Unknown Claims" (as defined below), against the "Released Persons" (as defined below):

- "Released Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, whether class or individual in nature, whether direct or derivative, whether fixed or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, which arise out of or relate in any way to both: (i) the purchase or acquisition of shares of Aegerion publicly traded common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were or could have been alleged by Lead Plaintiffs or any Class Member in the Litigation. "Released Claims" does not include claims to enforce the Settlement. "Released Claims" includes "Unknown Claims" as defined below.
- "Released Defendants' Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments, and causes of action of every nature and description (including Unknown Claims), whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, that arise out of or relate in any way to the institution, prosecution or settlement of the claims against Defendants in the Litigation, except for claims relating to the enforcement of the Settlement.
- "Released Persons" means each and all of the Defendants and their Related Parties.
- "Related Parties" means each of a Defendant's respective former, present or future parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, attorneys, advisors, accountants, auditors, and insurers and reinsurers of each of them; and the predecessors, successors, estates, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives and assigns of each of them, in their capacity as such.
- "Unknown Claims" means any and all Released Claims or Released Defendants' Claims that any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class

Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or to the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members. With respect to any and all Released Claims and Released Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

> **A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but the Settling Parties shall expressly settle and release, and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

EXCLUDING YOURSELF FROM THE CLASS

If you do not want to participate in this Settlement, and you want to keep the right to potentially sue the Defendants and the other Released Persons, on your own, about the claims being released by the Settlement, then you must take steps to remove yourself from the Class. This is called excluding yourself – or is sometimes referred to as "opting out."

11. How do I opt out of the Class and the proposed Settlement?

To exclude yourself from the Class and the Settlement, you must send a letter by First-Class Mail stating that you "request exclusion from the Class in the *Aegerion Securities Litigation*." You ***cannot*** exclude yourself by telephone or e-mail. Your letter must include your purchases, acquisitions, and sales of Aegerion publicly traded common stock during the Class Period, including the dates, the number of shares of Aegerion publicly traded common stock you purchased, acquired, or sold, and price paid or received for each such purchase, acquisition, or sale. In addition, you must include your name, address, telephone number, and your signature. Unless otherwise extended by the Court, you must submit your exclusion request so that it is **postmarked no later than October 31, 2017** to:

Aegerion Securities Litigation
Claims Administrator
EXCLUSIONS
c/o Gilardi & Co. LLC
3301 Kemer Blvd.
San Rafael, CA 94901

Unless otherwise altered by Order of the Court, your exclusion request must comply with the above requirements in order to be valid. If you ask to be excluded, you will not receive any payment from the Settlement, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue the Defendants and the other Released Persons about the Released Claims in the future.

12. If I do not exclude myself, can I sue the Defendants and the other Released Persons for the same thing later?

No. Unless you exclude yourself, you give up any rights you may potentially have to sue the Defendants and the other Released Persons for any and all Released Claims. If you have a pending lawsuit against the Released Persons, speak to your lawyer in that case immediately. You must exclude yourself from the Class in this Litigation to continue your own lawsuit. Remember, the exclusion deadline is October 31, 2017.

13. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you should not send in a Proof of Claim to ask for any money. But, if you do exclude yourself, you may have the right to potentially sue or be part of a different lawsuit against the Defendants and the other Released Persons.

THE LAWYERS REPRESENTING YOU

14. Do I have a lawyer in this case?

The Court ordered that the law firms of Robbins Geller Rudman & Dowd LLP and Motley Rice LLC represent the Class Members, including you. These lawyers are called Lead Counsel. If you want to be represented by your own lawyer, you may hire one at your own expense.

15. How will the lawyers be paid?

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount and for expenses and costs in an amount not to exceed $250,000 in connection with the Litigation, plus interest on such fees and expenses at the same rate as earned by the Settlement Fund. In addition, one or more of the Lead Plaintiffs will seek reimbursement for their time and expenses incurred in representing the Class in an amount not to exceed $17,500 in the aggregate. Such sums as may be approved by the Court will be paid from the Settlement Fund.

OBJECTING TO THE SETTLEMENT

You can tell the Court that you do not agree with the Settlement or any part of it.

16. How do I tell the Court that I object to the proposed Settlement?

If you are a Class Member, you can comment or object to the proposed Settlement, the proposed Plan of Allocation, Lead Counsel's fee and expense application, and/or Lead Plaintiffs' time and expense request. You can write to the Court setting out your comment or objection. The Court will consider your views. To comment or object, you must send a signed letter saying that you wish to comment on or object to the proposed Settlement in the *Aegerion Securities Litigation*. Include your name, address, daytime telephone number, e-mail address, and your signature, identify the date(s), price(s), and number(s) of shares of Aegerion publicly traded common stock you purchased, acquired, and sold during the Class Period, and state your comments or the reasons why you object to the proposed Settlement, Plan of Allocation and/or fee and expense application. You must also include copies of documents demonstrating such purchase(s), acquisition(s) and/or sale(s). Unless otherwise extended by Order of the Court, your comments or objection must be filed with the Court and mailed or delivered to each of the following addresses such that it is ***received*** **no later than October 31, 2017:**

COURT

U.S. DISTRICT COURT
DISTRICT OF MASS.
John Joseph Moakley
U.S. Courthouse
1 Courthouse Way, Suite 2300
Boston, MA 02210

LEAD COUNSEL

Ellen Gusikoff Stewart
ROBBINS GELLER
RUDMAN & DOWD LLP
655 West Broadway
Suite 1900
San Diego, CA 92101

DEFENDANTS' COUNSEL

Randall W. Bodner
ROPES & GRAY LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600

17. What is the difference between objecting and excluding?

Objecting is simply telling the Court that you do not like something about the Settlement. You can object **only** if you stay in the Class.

Excluding yourself is telling the Court that you do not want to be paid and do not want to release any claims you think you may have against Defendants and their Related Parties. If you exclude yourself, you cannot object to the Settlement because it does not affect you.

THE COURT'S SETTLEMENT HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement. You may attend and you may ask to speak, but you do not have to.

18. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Settlement Hearing at **2:00 p.m. ET, on November 30, 2017**, in the Courtroom of the Honorable Mark L. Wolf, at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210. At the hearing, the Court will consider whether the Settlement and the Plan of Allocation are fair, reasonable, and adequate. If there are objections, the Court will consider them, even if you do not ask to speak at the hearing. The Court will listen to people who attend the hearing. The Court may also issue a ruling on Lead Counsel's application for attorneys' fees and expenses (which request will include an application for reimbursement for Lead Plaintiffs' time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate). After the Settlement Hearing, the Court will decide whether to approve the Settlement and the Plan of Allocation. We do not know how long these decisions will take. You should be aware that the Court may change the date and time of the Settlement Hearing without another notice being sent to Class Members. If you want to attend the hearing, you should check with Lead Counsel or the Settlement website www.aegerionsecuritieslitigation.com beforehand to be sure that the date and/or time has not changed.

19. Do I have to come to the hearing?

No. Lead Counsel will answer questions the Court may have. But, you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but that is not necessary. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

20. May I speak at the hearing?

If you object to the Settlement, the Plan of Allocation, or the fee and expense application, you may ask the Court for permission to speak at the Settlement Hearing. To do so, you must include with your objection (*see* question 16 above) a statement saying that it is your "Notice of Intention to Appear in the *Aegerion Securities Litigation*." Persons who intend to object to the Settlement, the Plan of Allocation, and/or any attorneys' fees and expenses to be awarded to Lead Counsel (including any reimbursement to Lead Plaintiffs for their time and expenses representing the Class) and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Settlement Hearing. Unless otherwise extended by an Order of the Court, your notice of intention to appear must be **received** no later than October 31, 2017, and addressed to the Clerk of Court, Lead Counsel, and Defendants' counsel, at the addresses listed above in question 16.

You cannot speak at the hearing if you exclude yourself from the Class.

IF YOU DO NOTHING

21. What happens if I do nothing?

If you do nothing, you will not receive any money from this Settlement. In addition, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants and their Related Parties about the Released Claims in this case.

GETTING MORE INFORMATION

22. How do I get more information?

For even more detailed information concerning the matters involved in this Litigation, you can obtain answers to common questions regarding the proposed Settlement by contacting the Claims Administrator toll-free at 1-844-319-2120. Reference is also made to the Stipulation, to the pleadings in support of the Settlement, to the Orders entered by the Court, and to the other settlement-related papers filed in the Litigation, which are posted on the Settlement website at www.aegerionsecuritieslitigation.com, and which may be inspected at the Office of the Clerk of the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Suite 2300, Boston, MA 02210, during regular business hours. For a fee, all papers filed in this Litigation are available at www.pacer.gov.

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, www.rgrdlaw.com or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG CLASS MEMBERS

The Settlement Amount of $22.25 million and any interest earned thereon is the "Settlement Fund." The Settlement Fund, less all taxes, approved costs, fees, and expenses (the "Net Settlement Fund") shall be distributed to Class Members who submit timely and valid Proof of Claim forms to the Claims Administrator ("Authorized Claimants"). The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have an overall net loss on all of your transactions in Aegerion publicly traded common stock during the Class Period.

For purposes of formulating the Plan of Allocation and determining the amount an Authorized Claimant may recover under it, Lead Counsel have conferred with their damages consultant regarding the Plan of Allocation and it reflects an assessment of the damages that they believe could have been recovered by Class Members had Lead Plaintiffs prevailed at trial.

In the unlikely event there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's claim, as defined below. If, however, and as is more likely, the amount in the Net Settlement Fund is not sufficient to permit payment of the total claim of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's claim bears to the total of the claims of all Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants. Allowed claims will also be subjected to the statutory 90-day look-back amount provided for in the Private Securities Litigation Reform Act of 1995 ("PSLRA").[2]

The calculation of claims below is not an estimate of the amount you will receive. It is a formula for allocating the Net Settlement Fund among all Authorized Claimants. Furthermore, if any of the formulas set forth below yield an amount less than or equal to $0.00, the claim per share shall be $0.00.

A "claim" will be calculated as follows:

Aegerion Securities Litigation
CUSIP: 00767E102
April 30, 2013 – May 11, 2016

The Plan of Allocation is based on the following chart setting forth alleged inflation per share amounts for Class Period common stock purchases, acquisitions, and sales and also takes into account the mean trading price of Aegerion common stock during the PSLRA 90-day look-back period (which was $1.60).

Inflation Period	Alleged Inflation per Share
April 30, 2013 – January 9, 2014	$36.21
January 10, 2014 – May 6, 2014	$27.21
May 7, 2014 – October 30, 2014	$18.02
October 31, 2014 – July 5, 2015	$4.05
July 6, 2015 – November 9, 2015	$2.85
November 10, 2015 – May 11, 2016	$0.35
May 12, 2016 – thereafter	$0.00

For shares of Aegerion common stock ***purchased, or acquired, on or between April 30, 2013 through May 11, 2016***, the recovery per share shall be as follows:

a) If sold on or between April 30, 2013 through May 11, 2016, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition less the inflation per share at the time of sale; and (ii) the difference between the purchase or acquisition price and the selling price.

b) If retained beyond May 11, 2016 and sold on or before August 9, 2016, the recovery per share shall be the least of: (i) the inflation per share at the time of purchase or acquisition; (ii) the difference between the purchase or acquisition price and the selling price; and (iii) the difference between the purchase or acquisition price and the average closing price up to the date of sale as set forth in the table below.

[2] Pursuant to Section 21D(e)(1) of the PSLRA, "in any private action arising under this chapter in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market."

c) If retained at the close of trading on August 9, 2016, or sold thereafter, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition; and (ii) the difference between the purchase or acquisition price and $1.60.

Date	Closing Price	Average Closing Price
5/12/2016	$1.91	$1.91
5/13/2016	$1.73	$1.82
5/16/2016	$2.31	$1.98
5/17/2016	$1.89	$1.96
5/18/2016	$1.78	$1.92
5/19/2016	$1.67	$1.88
5/20/2016	$1.73	$1.86
5/23/2016	$1.64	$1.83
5/24/2016	$1.64	$1.81
5/25/2016	$1.61	$1.79
5/26/2016	$1.73	$1.79
5/27/2016	$1.82	$1.79
5/31/2016	$1.78	$1.79
6/1/2016	$1.93	$1.80
6/2/2016	$1.76	$1.80
6/3/2016	$1.71	$1.79
6/6/2016	$1.78	$1.79
6/7/2016	$1.68	$1.78
6/8/2016	$1.60	$1.77
6/9/2016	$1.50	$1.76
6/10/2016	$1.37	$1.74
6/13/2016	$1.26	$1.72
6/14/2016	$1.33	$1.70
6/15/2016	$1.71	$1.70
6/16/2016	$1.63	$1.70
6/17/2016	$1.69	$1.70
6/20/2016	$1.62	$1.70
6/21/2016	$1.53	$1.69
6/22/2016	$1.56	$1.69
6/23/2016	$1.67	$1.69
6/24/2016	$1.54	$1.68

Date	Closing Price	Average Closing Price
6/27/2016	$1.41	$1.67
6/28/2016	$1.47	$1.67
6/29/2016	$1.51	$1.66
6/30/2016	$1.49	$1.66
7/1/2016	$1.58	$1.65
7/5/2016	$1.47	$1.65
7/6/2016	$1.54	$1.65
7/7/2016	$1.65	$1.65
7/8/2016	$1.67	$1.65
7/11/2016	$1.62	$1.65
7/12/2016	$1.61	$1.65
7/13/2016	$1.58	$1.64
7/14/2016	$1.55	$1.64
7/15/2016	$1.51	$1.64
7/18/2016	$1.51	$1.64
7/19/2016	$1.48	$1.63
7/20/2016	$1.53	$1.63
7/21/2016	$1.49	$1.63
7/22/2016	$1.46	$1.62
7/25/2016	$1.47	$1.62
7/26/2016	$1.44	$1.62
7/27/2016	$1.55	$1.62
7/28/2016	$1.47	$1.61
7/29/2016	$1.44	$1.61
8/1/2016	$1.47	$1.61
8/2/2016	$1.44	$1.61
8/3/2016	$1.49	$1.60
8/4/2016	$1.51	$1.60
8/5/2016	$1.53	$1.60
8/8/2016	$1.54	$1.60
8/9/2016	$1.58	$1.60

The date of purchase or sale is the "contract" or "trade" date as distinguished from the "settlement" date. All purchase, acquisition, and sale prices shall exclude any fees and commissions. The receipt or grant by gift, devise or operation of law of Aegerion publicly traded common stock during the Class Period shall not be deemed a purchase or sale of Aegerion publicly traded common stock for the calculation of a claimant's recognized claim, nor shall it be deemed an assignment of any claim relating to the purchase of such shares unless specifically provided in the instrument of gift or assignment. The receipt of Aegerion publicly traded common stock during the Class Period in exchange for securities of any other corporation or entity shall not be deemed a purchase or sale of Aegerion publicly traded common stock.

For Class Members who held Aegerion publicly traded common stock at the beginning of the Class Period or made multiple purchases, acquisitions, or sales during the Class Period, the First-In, First-Out ("FIFO") method will be applied to such holdings, purchases, acquisitions, and sales for purposes of calculating a claim. Under the FIFO method, sales of Aegerion publicly traded common stock during the Class Period will be matched, in chronological order, first against shares of common stock held at the beginning of the Class Period. The remaining sales of common stock during the Class Period will then be matched, in chronological order, against common stock purchased or acquired during the Class Period.

A Class Member will be eligible to receive a distribution from the Net Settlement Fund only if a Class Member had a net overall loss, after all profits from transactions in all Aegerion common stock described above during the Class Period are subtracted from all losses. However, the proceeds from sales of common stock that have been matched against the common stock held at the beginning of the Class Period will not be used in the calculation of such net loss. No distributions will be made to Authorized Claimants who would otherwise receive a distribution of less than $10.00.

Payment pursuant to the Plan of Allocation set forth above shall be conclusive against all Authorized Claimants. Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability

whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. No Person shall have any claim against Lead Plaintiffs, Lead Plaintiffs' Counsel, the Claims Administrator, or other Person designated by Lead Counsel, Defendants, or Defendants' counsel based on distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. All Class Members who fail to complete and submit a valid and timely Proof of Claim shall be barred from participating in distributions from the Net Settlement Fund (unless otherwise ordered by the Court), but otherwise shall be bound by all of the terms of the Stipulation, including the terms of any judgment entered and the releases given.

Please contact the Claims Administrator or Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim. If you are unsatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class Members and the claims administration process, to decide the issue by submitting a written request.

Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. Lead Plaintiffs and Lead Plaintiffs' Counsel, likewise, will have no liability for their reasonable efforts to execute, administer, and distribute the Settlement.

Distributions will be made to Authorized Claimants after all claims have been processed and after the Court has finally approved the Settlement. If any funds remain in the Net Settlement Fund by reason of un-cashed distribution checks or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Class Members who are entitled to participate in the distribution of the Net Settlement Fund cash their distributions, any balance remaining in the Net Settlement Fund after at least six (6) months after the initial distribution of such funds shall be used: (a) first, to pay any amounts mistakenly omitted from the initial disbursement; (b) second, additional settlement administration fees, costs, and expenses, including those of Lead Plaintiffs' Counsel as may be approved by the Court; and (c) to make a second distribution to claimants who cashed their checks from the initial distribution and who would receive at least $10.00, after payment of the estimated costs, expenses, or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. These redistributions shall be repeated, if economically feasible, until the balance remaining in the Net Settlement Fund is *de minimis* and such remaining balance shall then be distributed to an appropriate non-sectarian, non-profit charitable organization serving the public interest selected by Lead Counsel and approved by the Court.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased or acquired Aegerion publicly traded common stock during the Class Period for the beneficial interest of an individual or organization other than yourself, the Court has directed that, WITHIN SEVEN (7) DAYS OF YOUR RECEIPT OF THIS NOTICE, you either (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or which you purchased or acquired such securities during such time period, or (b) request additional copies of this Notice and the Proof of Claim form, which will be provided to you free of charge, and within ten (10) days mail the Notice and Proof of Claim form directly to the beneficial owners of the securities referred to herein. If you choose to follow alternative procedure (b), upon such mailing, you must send a statement to the Claims Administrator confirming that the mailing was made as directed and retain the names and addresses for any future mailings to Class Members. You are entitled to reimbursement from the Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, including reimbursement of postage expense and the cost of ascertaining the names and addresses of beneficial owners. Your reasonable expenses will be paid upon request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator:

Aegerion Securities Litigation
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box 30253
College Station, TX 77842-3253
www.aegerionsecuritieslitigation.com

DATED: June 29, 2017

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

EXHIBIT B

I. GENERAL INSTRUCTIONS

1. To recover as a Member of the Class based on your claims in the action entitled *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 1:14-cv-10105-MLW (the "Litigation"), you must complete and, on page 6 hereof, sign this Proof of Claim and Release form ("Proof of Claim"). If you fail to submit a timely and properly addressed (as set forth in paragraph 3 below) Proof of Claim, your claim may be rejected and you may not receive any recovery from the Net Settlement Fund created in connection with the proposed Settlement.

2. Submission of this Proof of Claim, however, does not assure that you will share in the proceeds of the Settlement of the Litigation.

3. YOU MUST MAIL OR SUBMIT ONLINE YOUR COMPLETED AND SIGNED PROOF OF CLAIM, ACCOMPANIED BY COPIES OF THE DOCUMENTS REQUESTED HEREIN, NO LATER THAN NOVEMBER 17, 2017, ADDRESSED AS FOLLOWS:

Aegerion Securities Litigation
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box 30253
College Station, TX 77842-3253
Online Submissions: www.aegerionsecuritieslitigation.com

4. If you are NOT a Member of the Class, as defined in the Notice of Proposed Settlement of Class Action ("Notice"), DO NOT submit a Proof of Claim.

5. If you are a Member of the Class and you did not timely request exclusion, you will be bound by the terms of any judgment entered in the Litigation, including the releases provided therein, WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM.

II. CLAIMANT IDENTIFICATION

If you purchased or acquired Aegerion Pharmaceuticals, Inc. ("Aegerion") publicly traded common stock and held the certificate(s) in your name, you are the beneficial purchaser or acquirer as well as the record purchaser or acquirer. If, however, you purchased or acquired Aegerion publicly traded common stock and the certificate(s) were registered in the name of a third party, such as a nominee or brokerage firm, you are the beneficial purchaser or acquirer and the third party is the record purchaser or acquirer.

Use Part I of this form entitled "Claimant Identification" to identify each purchaser or acquirer of record ("nominee"), if different from the beneficial purchaser or acquirer of the Aegerion publicly traded common stock that forms the basis of this claim. THIS CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL PURCHASER(S) OR ACQUIRER(S) OR THE LEGAL REPRESENTATIVE OF SUCH PURCHASER(S) OR ACQUIRER(S) OF THE AEGERION PUBLICLY TRADED COMMON STOCK UPON WHICH THIS CLAIM IS BASED.

Separate Proofs of Claim should be submitted for each separate legal entity (for example, a claim by joint owners should not include the transactions of just one of the joint owners, and an individual should not submit one claim that combines his or her IRA transactions with transactions made solely in the individual's name). Conversely, a combined Proof of Claim should be submitted on behalf of each legal entity (including an individual) that includes all transactions made by that entity, no matter how many separate accounts that entity has (for example, a corporation/individual with multiple brokerage accounts should include all transactions made in Aegerion publicly traded common stock during the Class Period on one Proof of Claim, no matter in how many accounts the transactions were made).

All joint purchasers or acquirers must sign this claim. Executors, administrators, guardians, conservators, and trustees or others acting in a representative capacity on behalf of a Class Member must complete and sign this claim on behalf of persons represented by them, and submit evidence of their current authority to act on behalf of that Class Member, including that your titles or capacities must be stated. The Social Security (or taxpayer identification) number and telephone number of the beneficial owner may be used in verifying the claim. Failure to provide the foregoing information could delay verification of your claim or result in rejection of the claim.

III. CLAIM FORM

Use Part II of this form entitled "Schedule of Transactions in Aegerion Publicly Traded Common Stock" to supply all required details of your transaction(s) in Aegerion publicly traded common stock. If you need more space or additional schedules, attach separate sheets giving all of the required information in substantially the same form. Sign and print or type your name on each additional sheet.

On the schedules, provide all of the requested information with respect to ***all*** of your purchases or acquisitions and ***all*** of your sales of Aegerion publicly traded common stock which took place during the period April 30, 2013 through and including August 9, 2016, whether such transactions resulted in a profit or a loss. You must also provide all of the requested information with respect to ***all*** of the shares of Aegerion publicly traded common stock you held at the close of trading on April 29, 2013, May 11, 2016, and August 9, 2016. Failure to report all such transactions may result in the rejection of your claim.

List each transaction separately and in chronological order, by trade date, beginning with the earliest. You must accurately provide the month, day, and year of each transaction you list.

The date of covering a "short sale" is deemed to be the date of purchase of Aegerion publicly traded common stock. The date of a "short sale" is deemed to be the date of sale of Aegerion publicly traded common stock.

For each transaction, copies of broker confirmations or other documentation of your transactions in Aegerion publicly traded common stock should be attached to your claim. Failure to provide this documentation could delay verification of your claim or result in rejection of your claim.

A purchase or sale of Aegerion publicly traded common stock shall be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date; please provide any "contract" or "trade" dates in your claim.

NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. This is different from the online submission process that is available at www.aegerionsecuritieslitigation.com. If you have a large number of transactions and wish to file your claim electronically, you must contact the Claims Administrator at edata@gilardi.com to obtain the required file layout.

[redacted]

Must Be Postmarked (if Mailed) or Received (if Submitted Online) No Later Than November 17, 2017

Official Office Use Only

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.

Case No. 1:14-cv-10105-MLW

AXG

PROOF OF CLAIM AND RELEASE

Please Type or Print in the Boxes Below
Do NOT use Red Ink, Pencil, or Staples

PART I: CLAIMANT IDENTIFICATION

Last Name | M.I. | First Name

Last Name (Co-Beneficial Owner) | M.I. | First Name (Co-Beneficial Owner)

○ IRA ○ Joint Tenancy ○ Employee ○ Individual ○ Other_____ (specify)

Company Name (Beneficial Owner - If Claimant is not an Individual) or Custodian Name if an IRA

Trustee/Asset Manager/Nominee/Record Owner's Name (If Different from Beneficial Owner Listed Above)

Account#/Fund# (Not Necessary for Individual Filers)

Last Four Digits of Social Security Number or Taxpayer Identification Number

Telephone Number (Primary Daytime) Telephone Number (Alternate)

Email Address

MAILING INFORMATION

Address

Address

City | State | Zip Code

Foreign Province | Foreign Postal Code | Foreign Country Name/Abbreviation

FOR CLAIMS PROCESSING ONLY	OB	CB	○ ATP ○ KE ○ ICI	○ BE ○ DR ○ EM	○ FL ○ ME ○ ND	○ OP ○ RE ○ SH	/ /	FOR CLAIMS PROCESSING ONLY

PART II. SCHEDULE OF TRANSACTIONS IN AEGERION PUBLICLY TRADED COMMON STOCK

A. Number of shares of Aegerion publicly traded common stock held at the close of trading on April 29, 2013: _____ Proof Enclosed? ◯ Y ◯ N

B. Purchases or acquisitions of Aegerion publicly traded common stock (April 30, 2013 – August 9, 2016, inclusive):

PURCHASES

	Trade Date(s) of Shares (List Chronologically)	Number of Shares Purchased or Acquired	Total Purchase or Acquisition Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Purchase Enclosed?
	M M / D D / Y Y Y Y			
1.	/ /		$ _____ .00	◯ Y ◯ N
2.	/ /		$ _____ .00	◯ Y ◯ N
3.	/ /		$ _____ .00	◯ Y ◯ N
4.	/ /		$ _____ .00	◯ Y ◯ N
5.	/ /		$ _____ .00	◯ Y ◯ N

IMPORTANT: (i) If any purchase listed covered a "short sale," please mark Yes: ◯ Yes

(ii) If you received shares through an acquisition or merger, please identify the date, the share amount and the company acquired:

M M / D D / Y Y Y Y Merger Shares: _____ Company: _____

C. Sales of Aegerion publicly traded common stock (April 30, 2013 – August 9, 2016, inclusive):

SALES

	Trade Date(s) of Shares (List Chronologically)	Number of Shares Sold	Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
	M M / D D / Y Y Y Y			
1.	/ /		$ _____ .00	◯ Y ◯ N
2.	/ /		$ _____ .00	◯ Y ◯ N
3.	/ /		$ _____ .00	◯ Y ◯ N
4.	/ /		$ _____ .00	◯ Y ◯ N
5.	/ /		$ _____ .00	◯ Y ◯ N

D. Number of shares of Aegerion publicly traded common stock held at the close of trading on May 11, 2016: _____ Proof Enclosed? ◯ Y ◯ N

E. Number of shares of Aegerion publicly traded common stock held at the close of trading on August 9, 2016: _____ Proof Enclosed? ◯ Y ◯ N

IF YOU REQUIRE ADDITIONAL SPACE, ATTACH EXTRA SCHEDULES IN THE SAME FORMAT AS ABOVE. SIGN AND PRINT YOUR NAME ON EACH ADDITIONAL PAGE.

YOU MUST READ AND SIGN THE RELEASE ON PAGE 6. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.

IV. SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

On behalf of myself (ourselves) and each of my (our) heirs, agents, executors, trustees, administrators, predecessors, successors and assigns, I (we) submit this Proof of Claim under the terms of the Stipulation of Settlement described in the Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Massachusetts with respect to my (our) claim as a Class Member and for purposes of enforcing the release set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Litigation. I (We) agree to furnish additional information to the Claims Administrator to support this claim (including transactions in other Aegerion securities) if requested to do so. I (We) have not submitted any other claim covering the same purchases, acquisitions, or sales of Aegerion publicly traded common stock during the Class Period and know of no other person having done so on my (our) behalf.

V. RELEASE

1. Upon the Effective Date of the Settlement, I (we) acknowledge full and complete satisfaction of, and fully, finally, and forever settle, release, and discharge from the Released Claims each and all of the "Released Persons," defined as each and all of the Defendants and their Related Parties. "Related Parties" means each of a Defendant's respective former, present or future parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, attorneys, advisors, accountants, auditors, and insurers and reinsurers of each of them; and the predecessors, successors, estates, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives and assigns of each of them, in their capacity as such.

2. "Released Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, whether class or individual in nature, whether direct or derivative, whether fixed or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, which arise out of or relate in any way to both: (i) the purchase or acquisition of shares of Aegerion publicly traded common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were or could have been alleged by Lead Plaintiffs or any Class Members in the Litigation. "Released Claims" does not include claims to enforce the Settlement. "Released Claims" includes "Unknown Claims" as defined below.

3. "Unknown Claims" means any and all Released Claims or Released Defendants' Claims that any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or to the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members. With respect to any and all Released Claims and Released Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

> **A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but the Settling Parties shall expressly settle and release, and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

4. I (We) hereby warrant and represent that I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any matter released pursuant to this release or any other part or portion thereof.

5. I (We) hereby warrant and represent that I (we) have included the information requested about all of my (our) transactions in Aegerion publicly traded common stock which are the subject of this claim, which occurred during the Class Period, as well as the opening and closing positions in such securities held by me (us) on the dates requested in this claim form.

I declare under penalty of perjury under the laws of the United States of America that all of the foregoing information supplied on this Proof of Claim by the undersigned is true and correct.

Executed this_____ day of _____ in _____
(Month/Year) (City/State/Country)

_____	_____
(Sign your name here)	(Sign your name here)
_____	_____
(Type or print your name here)	(Type or print your name here)
_____	_____
(Capacity of person(s) signing, *e.g.*, Beneficial Purchaser or Acquirer, Executor or Administrator)	(Capacity of person(s) signing, *e.g.*, Beneficial Purchaser or Acquirer, Executor or Administrator)

ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME.
THANK YOU FOR YOUR PATIENCE.

Reminder Checklist:

1. Please sign the above release and declaration.
2. If this claim is being made on behalf of Joint Claimants, then both must sign.
3. Remember to attach copies of supporting documentation, if available.
4. **Do not send** originals of certificates.
5. Keep a copy of your claim form and all supporting documentation for your records.
6. If you desire an acknowledgment of receipt of your claim form please send it Certified Mail, Return Receipt Requested.
7. If you move, please send your new address to the address below.
8. **Do not use red pen or highlighter** on the Proof of Claim or supporting documentation.

THIS PROOF OF CLAIM MUST BE POSTMARKED (IF MAILED) OR RECEIVED (IF SUBMITTED ONLINE) NO LATER THAN NOVEMBER 17, 2017, ADDRESSED AS FOLLOWS:

Aegerion Securities Litigation
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box 30253
College Station, TX 77842-3253
Online Submissions: www.aegerionsecuritieslitigation.com

Exhibit C

Gilardi & Co LLC
3301 Kerner Blvd.
San Rafael, CA 94901
P: (415) 461-0410
F: (415) 461-0412

July 20, 2017

«FirstName» «LastName»
«Company»
«Addr1»
«Addr2»
South Bend, IN 46601
«FCountry»

Re: **Aegerion Securities Litigation**

Dear «GENDER» «LastName»:

Please find enclosed the Notice and Proof of Claim and Release for the above referenced litigation. Please note both the class period and the designated eligible securities described on page one of the Notice, specifically the inclusion of all persons who purchased or otherwise acquired the publicly traded common stock of Aegerion Pharmaceuticals, Inc. during the period from April 30, 2013 through and including May 11, 2016. In addition, the Notice provides that the Exclusion Deadline is October 31, 2017, and that the Claim Filing Deadline is November 17, 2017.

Please pay particular attention to the "Special Notice to Securities Brokers and Other Nominees" on page eleven of the Notice, which requires your attention WITHIN SEVEN (7) DAYS OF YOUR RECEIPT OF THIS NOTICE. Please do not make your own copies of the Proof of Claim Form, as copies may not be accepted for processing. Additional copies of the appropriate documents may be requested by contacting us at the above address and/or phone number.

If we conduct the necessary mailing on your behalf, please submit names and addresses either via email to Notifications@Gilardi.com, via CD Rom to the above address or contact (415) 458-3015 to obtain secure FTP transmission instructions. Mailing labels will be accepted, but you may be requested to provide an additional copy of the address information you send. Do not include any confidential information that should not appear on a mailing label.

The data provided must be in one of the following formats:

- ASCII Fixed Length file
- ASCII Tab Delimited file
- Microsoft Excel spreadsheet

Your request must also specify the case name and Control Total(s) (for example, the total number of name and address records provided) for each file submission.

If you have any questions, please call (415) 458-3015.

Sincerely,
Gilardi & Co. LLC

Exhibit D

Declaration of Publication

I, Dominic Campodonico, as Senior Project Manager, Legal Notification Services at Gilardi & Co. LLC, a KCC Class Action Services Company in San Rafael, California, hereby certify that I caused the attached notice to be printed in said publication on July 25, 2017:

Name of Publication:	The Wall Street Journal
Address:	1211 Avenue of the Americas
City, State, Zip	New York, NY, 10036
Phone #:	1-800-568-7625
State of:	New York

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 28th day of September 2017, at San Rafael, California.

Dominic Campodonico

Arconic Weighs In on Deadly London Fire

BY BOB TITA

Arconic Inc. said it had no control over the use of the aluminum composite panels on the exterior of a London apartment tower where a fire last month killed 80 people, but will continue to refrain from selling the product for use in high-rise buildings.

Investigators suspect that Arconic's Reynobond PE panels contributed to the spread of the June 14 fire at Grenfell Tower. The panels' polyethylene cores are believed to have ignited during the fire, which investigators suspect started in an apartment and spread to the building's exterior cladding.

The potential fallout from the fire has added to the pressures on a company that also had to fight a proxy battle earlier this year and address quality issues related to parts used in aircraft engines, a key growth market.

Interim Chief Executive David Hess said Monday that Arconic continues to support the Grenfell investigation. "We believe we've been compliant in the sale of our product," he told analysts after Arconic reported forecast-beating profit and boosted its full-year guidance.

Arconic announced June 26 that it would stop selling the panels for use in high-rise buildings, though the company continues to sell them for use in low-rise structures. The company also markets panels with fire-retardant cores that can be used in high rises. World-side sales of Reynobond PE panels for building applications were less than $60 million last year, Arconic said. The U.K. accounted for about 5%, or $3 million, of those sales.

The company said the Reynobond PE panels are certified for use as a construction material in the U.K. and other countries, and IT sells them with the expectation that they will be used in accordance with local building regulations.

Mr. Hess sidestepped a question about the company's ability to handle potential liability costs for the Grenfell fire, saying only that "we have appropriate insurance coverage. I really can't speculate on our exposure." Concerning the fire, Mr. Hess said, "We extend our deepest sympathies to those who have lost so much."

New York-based Arconic has stressed that the Reynobond panels were one component of a wall-cladding assembly on Grenfell Tower featuring insulation and other materials that were put together by architects, contractors, fabricators and others who are responsible for complying with specific regulations.

"When we sell that material, we don't know where that material is headed when it's sold," Mr. Hess said. "We supply the building material. We do not control the ultimate design and installation."

Mr. Hess said the search for a permanent CEO at Arconic continues, and an executive search firm has been hired to help the board. Activist investor Elliott Management agreed in May to call off its proxy fight in exchange for additional appointments to the Arconic board.

It is believed that Elliott's preferred candidate for the job, veteran aerospace executive Larry Lawson, is among those under consideration. Mr. Hess declined to comment on the candidates or the selection process.

Former CEO Klaus Kleinfeld left abruptly in April after heavy pressure from Elliott, which blamed him for lowering profit targets and failing to cut expenses.

Arconic raised its full-year outlook, lifting the range of expected sales to $12.3 billion to $12.7 billion from previous guidance of $11.8 billion to $12.4 billion. Arconic also boosted the floor on its adjusted per-share earnings forecast by 5 cents, to a range of $1.15 to $1.20.

The company has been under pressure to cut costs since splitting from aluminum maker Alcoa Inc. in November. The company's adjusted earnings margin before taxes rose to 14.9% from 14.7%.

Arconic reported profit of $212 million, or 43 cents a share, compared with $135 million, or 27 cents a share, a year earlier. Revenue edged up 0.8% to $3.26 billion.

—*Imani Moise contributed to this article.*



DAN KITWOOD/GETTY IMAGES

A June 14 fire killed 80 people at Grenfell Tower in London.

ADVERTISEMENT

Legal Notices

To advertise: 800-366-3975 or WSJ.com/classifieds

CLASS ACTIONS

If you bought Aegerion Pharmaceuticals, Inc. stock between April 30, 2013 and May 11, 2016, you could get a payment from a class action settlement.

A settlement has been proposed in a class action lawsuit captioned *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 14-cv-10105-MLW, concerning the price of Aegerion Pharmaceuticals, Inc. stock. The settlement will provide $22.25 million to pay claims from Aegerion investors who bought or acquired the company's stock from April 30, 2013, through and including May 11, 2016. If you qualify, you may send in a claim form to get benefits, or you can exclude yourself from the settlement, or you can object to it.

A hearing will be held on November 30, 2017, at 2:00 p.m. ET, before the Honorable Mark L. Wolf, at the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210, to consider whether to approve the settlement and a request by the lawyers representing all Class Members for an award of attorneys' fees of 25% of the $22.25 million settlement amount, plus expenses not to exceed $250,000, and a request by each of the Lead Plaintiffs for reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate.

If you purchased or acquired Aegerion publicly traded common stock between April 30, 2013 and May 11, 2016, inclusive, your rights may be affected by this Litigation and the settlement thereof. If you have not received a detailed Notice of Proposed Settlement of Class Action and a copy of the Proof of Claim and Release form, you may obtain copies by writing to *Aegerion Securities Litigation*, Claims Administrator, c/o Gilardi & Co. LLC, P.O. Box 30253, College Station, TX 77842-3253 or by downloading this information at www.aegerionsecuritieslitigation.com. You may also review the Stipulation of Settlement and all other settlement-related documents at www.aegerionsecuritieslitigation.com, or you may contact the Claims Administrator at 1-844-319-2120 for further information regarding the Settlement. You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

If you are a Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release online at www.aegerionsecuritieslitigation.com by November 17, 2017, or postmarked no later than November 17, 2017, establishing that you are entitled to a recovery. You will be bound by any judgment rendered in the Litigation unless you request to be excluded, in writing, to *Aegerion Securities Litigation*, Claims Administrator, EXCLUSIONS, c/o Gilardi & Co. LLC, 3301 Kerner Blvd., San Rafael, CA 94901, postmarked by October 31, 2017.

Any objection to any aspect of the settlement must be filed with the Clerk of the Court on or before October 31, 2017, and also delivered by hand or first-class mail to:

ROBBINS GELLER RUDMAN & DOWD LLP
ELLEN GUSIKOFF STEWART
655 West Broadway, Suite 1900
San Diego, CA 92101
1-800-449-4900

ROPES & GRAY LLP
RANDALL W. BODNER
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600
1-617-951-7000

The Court has retained the discretion to alter any of the deadlines or requirements outlined above for good cause shown.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE.

DATED: June 29, 2017

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

NOTICE OF SALE

Notice Of Secured Party's Public Sale Of Collateral Under Uniform Commercial Code

PLEASE TAKE NOTICE that on **Tuesday, August 1, 2017, at 10:00 A.M. local time,** West 126th Street Mezz Lender LLC ("Secured Party"), will offer for sale at a public auction, and sell to the highest "qualified bidder," **at the office of Cole Schotz P.C., 1325 Avenue of the Americas, 19th Floor, New York, New York 10019,** under Section 9-610 of the Uniform Commercial Code as enacted in the State of New York, all of Secured Party's right, title, and interest as a secured creditor of Columbia Lawrence Holdings 1 LLC, a New York limited liability company ("Debtor 1") and Columbia Lawrence Holdings 2 LLC, a New York limited liability company ("Debtor 2," together with Debtor 1, the "Debtor") in 100% of the membership interests in 126 Columbia Tower 1 LLC, a New York limited liability company, and 126 Columbia Tower 2 LLC, a New York limited liability company (collectively, the "Issuer"), pledged to Secured Party by Debtor. The principal asset of Debtor is 100% of the limited liability company interests in the Issuer and certain related rights and property relating thereto (collectively, the "Collateral"). Secured Party is informed and believes that Issuer owns certain real property known as: 402-410, 412-414, 416, 418, 420 and 422 West 126th Street, NY, NY; 429 West 126th Street, NY, NY; 422 West 127th Street, NY, NY; and 423 West 126th Street, NY, NY. This sale will be held to enforce the rights of Secured Party under (i) that certain Mezzanine Loan Agreement dated as of November 19, 2015, and (ii) those certain two (2) LLC Membership Interest Pledge Agreements dated as of November 19, 2015, executed by Debtor 1 and Debtor 2, respectively, in favor of Secured Party. The sale will be **FINAL** and on an **"AS-IS, WHERE IS"** basis and will be made **WITHOUT REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO TITLE, QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, POSSESSION, QUIET ENJOYMENT, OR ANY OTHER MATTER.** Secured Party reserves the right to establish other reasonable bidding procedures and to require potential bidders to reasonably demonstrate their ability to perform and close on the acquisition of the Collateral to the satisfaction of Secured Party. Secured Party reserves the right to credit bid at the auction. Secured Party also reserves the right to adjourn continue, or cancel the auction without further notice. Any parties interested in further information about the Collateral, becoming a "qualified bidder," and/or the terms of the sale should contact Jonathan Cuticelli of Sheldon Good & Company at (800) 516-0015 or jcuticelli@sheldongood.com. Qualified bidders may obtain a confidentiality agreement by visiting **http://www.SheldonGood.com.** Any prospective bidder must satisfy the requirements to be a "qualified bidder" by no later than 9:00 A.M. local time, on Tuesday, August 1, 2017. The sale will be conducted by Jonathan Cuticelli, Sheldon Good & Company, a New York licensed auctioneer, license No. 1387302.

BANKRUPTCIES

[illegible]

[illegible] that, by orders dated 20 July 2017 (the "Orders") made in the above matters, the Grand Court of the Cayman Islands (the "Court") has directed that four separate meetings (the "Scheme Meetings") be convened of certain creditors of Drillships Financing Holding Inc. ("DFH"), Ocean Rig UDW Inc. ("UDW"), Drill Rigs Holdings Inc. ("DRH") and Drillships Ocean Ventures Inc. ("DOV") (each in provisional liquidation) (each a "Company" and together, the "Companies") for the purpose of considering and, if thought fit, approving (with or without modification) a scheme of arrangement (together the "Schemes") in respect of each Company pursuant to section 86 of the Companies Law (2016 Revision) of the Cayman Islands (the "Companies Law") proposed to be made between each of the Companies and their respective Scheme Creditors.

[illegible]. The Scheme Creditors are as follows:

UDW Scheme Creditors
• the persons with a beneficial interest as principal in the 7.25 per cent senior unsecured notes due 30 April 2019 issued by UDW pursuant to an indenture dated 26 March 2014 (the "2019 Notes");
• the lenders of record under the DFH credit facility dated 12 July 2014 having guarantee claims against UDW pursuant to the terms of the DFH guarantee agreement dated 12 July 2013 (the "DFH Credit Facility");
• the lenders of record under the DOV credit facility dated 25 July 2014 having guarantee claims against UDW pursuant to the terms of the DOV guarantee agreement dated 25 July 2014 (the "DOV Credit Facility"); and
• the persons with a beneficial interest as principal in the 6.5 per cent senior secured notes due 1 October 2017 issued by DRH having guarantee claims against UDW pursuant to the terms of the DRH indenture dated 20 September 2012 (the "2017 Notes").

DRH Scheme Creditors
• the persons with a beneficial interest as principal in the 2017 Notes.

DFH Scheme Creditors
• the lenders of record under the DFH Credit Facility.

DOV Scheme Creditors
• the lenders of record under the DOV Credit Facility.

[illegible]. Each of the Scheme Meetings will be held at the offices of Maples and Calder, Ugland House, South Church Street, George Town, Cayman Islands on 11 August 2017 at the following times:
• UDW: 10 a.m. (Cayman Islands time);
• DRH: 10:30 a.m. (Cayman Islands time) or as soon thereafter as the UDW meeting is complete;
• DOV: 11 a.m. (Cayman Islands time) or as soon thereafter as the DRH meeting is complete; and
• DFH: 11:30 a.m. (Cayman Islands time) or as soon thereafter as the DOV meeting is complete;

at which places and times all Scheme Creditors as of the record date of 5:00 p.m. (Cayman Islands time) on 10 August 2017 will be entitled to vote. All Scheme Creditors are requested to attend and attendance and voting at the Scheme Meetings can be in person or by proxy in accordance with the voting instructions set out in the Explanatory Statement. A telephone dial-in facility will be made available for those Scheme Creditors who have submitted proxy forms. Scheme Creditors will be able to obtain the telephone dial-in details for the Scheme Meeting from the Information Agent (contact details below) and can request these up to the Submission Deadline (being 5:00 p.m. (Cayman Islands time) on 9 August 2017).

[illegible]. Any person entitled to attend the Scheme Meetings can obtain a copy of the relevant Scheme(s) of Arrangement, together with the relevant form of proxy and an explanatory statement explaining the effect of the Schemes of Arrangement (the "Explanatory Statement") on request to the Information Agent by calling +1 855-631-6346 (toll-free US and Canada) or +1 917-460-0913 (international) or by email to [illegible] or on request to the Joint Provisional Liquidators (the "JPLs") by calling +44 20 7098 7400 or +1 345 946 0081 or by email to [illegible] or [illegible]. A copy of the Explanatory Statement, which contains the Schemes of Arrangement, together with the relevant voting forms, has been made available to the Scheme Creditors through the Information Agent website at [illegible]. Notice of the Scheme Meetings has been sent to the Administrative Agents in respect of the DOV Credit Facility and the DFH Credit Facility respectively, and the Indenture Trustees in respect of the 2019 Notes and 2017 Notes respectively and to those parties which have registered with the Information Agent as a Scheme Creditor.

[illegible]. NOTICE IS FURTHER GIVEN THAT, if approved at the Scheme Meetings, the Schemes of Arrangement will be subject to subsequent applications seeking the sanction of the Court, which shall be heard at 10 a.m. (Cayman Islands time) on 4 September 2017 or as soon as practicable thereafter as they may be heard.

Dated: 21 July 2017

Maples and Calder, Cayman Islands
legal advisers to the Companies

Jury Backs AbbVie Payment

BY PETER LOFTUS

A federal-court jury in Chicago ordered drugmaker **AbbVie Inc.** to pay $150 million in punitive damages to an Oregon man after finding the company liable for fraudulent misrepresentations about the safety of the testosterone-replacement therapy AndroGel, according to court records.

The case was the first to go to trial of more than 4,000 lawsuits against AbbVie claiming AndroGel harmed patients, and that the North Chicago, Ill., company failed to properly warn doctors and patients about its risks.

The Oregon man, Jesse Mitchell, had filed a lawsuit against AbbVie in 2014, claiming that his use of AndroGel for several years caused a heart attack in 2012. He accused AbbVie of failing to properly warn doctors and patients that the drug carried an increased risk of heart attacks and strokes.

The lawsuit said AbbVie relayed positive information about AndroGel while omitting cardiac risks in its advertisements, and that AbbVie spent $80 million promoting AndroGel in the U.S. in 2012.

The jury in U.S. District Court for the Northern District of Illinois found AbbVie not strictly liable or negligent in Mr. Mitchell's heart attack, according to court records. But it found the company liable for "fraudulent misrepresentation," ending a trial that began in early July.

Mr. Mitchell's attorney, Troy Rafferty, said the jury found that AbbVie's fraudulent misrepresentation caused Mr. Mitchell's injury.

4,000
Lawsuits faced by AbbVie from patients who used AndroGel

AbbVie had argued at trial that Mr. Mitchell's heart attack was caused by other risk factors not related to AndroGel.

An AbbVie spokeswoman said: "The jury found that AndroGel did not cause any damage. We expect the punitive damage award will not stand." The jury didn't award compensatory damages to Mr. Mitchell, AbbVie said.

Some studies have suggested AndroGel and similar testosterone-replacement therapies increased patients' risk of heart problems, and in 2015 the U.S. Food and Drug Administration strengthened warnings in the drugs' prescribing labels about cardiovascular risks.

The FDA also said the drugs' benefits weren't established in men whose testosterone levels had fallen due to aging.

AbbVie had boosted AndroGel sales to an annual peak of more than $1.1 billion in 2012 with an aggressive marketing campaign including television commercials that urged men with low testosterone to talk to their doctors about treatment options. AbbVie and other drugmakers helped popularize the term "Low-T" to describe the condition. The drug is approved to treat low testosterone levels in males due to certain medical conditions.

AndroGel sales have declined in recent years and were $675 million in 2016.

Exchange-Traded Portfolios | WSJ.com/ETFresearch

Largest 100 exchange-traded funds, latest session

Monday, July 24, 2017

ETF	Symbol	Closing Price	Chg (%)	YTD (%)
AlerianMLPETF	AMLP	11.90	0.59	-6.1
ConsDiscSelSector	XLY	90.13	-0.36	11.6
ConsStapleSelSector	XLP	54.90	-0.20	6.1
DBGoldDoubleLgETN	DGP	79.37	-0.65	16.2
DBGoldDoubleShrt	DZZ	5.79	-0.28	-15.4
DeutscheXtrMSCIEAFE	DBEF	30.12	-0.26	7.3
EnSelectSectorSPDR	XLE	64.99	-0.18	-13.9
FinSelSectorSPDR	XLF	24.91	0.04	7.1
GuggS&P500EW	RSP	94.24	-0.07	9.8
HealthCareSelSect	XLV	78.90	-0.04	17.4
IndSelSectorSPDR	XLI	68.43	-0.20	10.1
iShIntermCredBd	CIU	110.15	-0.04	1.8
iSh1-3YCreditBond	CSJ	105.45	-0.02	0.5
iSh3-7YTreasuryBd	IEI	123.91	-0.10	1.1
iShCoreMSCIEAFEETF	IEFA	62.45	-0.20	25.2
iShCoreMSCIEmgMk	IEMG	52.75	0.36	24.1
iShCoreMSCITotIntl	IXUS	59.87	-0.03	17.8
iShCoreS&P500ETF	IVV	248.47	-0.02	10.4
iShCoreS&PMidCp	IJH	177.16	0.20	7.1
iShCoreS&PSmCpETF	IJR	71.46	0.01	3.4
iShS&PTotlUSStkMkt	ITOT	56.35	...	10.5
iShCoreUSAggBd	AGG	109.87	-0.05	1.6
iShSelectDividend	DVY	92.60	-0.20	4.6
iShEdgeMSCIMinEAFE	EFAV	70.11	-0.05	14.5
iShEdgeMSCIMinUSA	USMV	49.58	-0.20	9.6
iShGoldTr	IAU	12.00	0.17	9.2
iShiBoxx$InvGrCpBd	LQD	121.41	-0.12	3.6
iShiBoxx$HYCpBd	HYG	88.32	0.06	3.5
iShJPMUSDEmgBd	EMB	115.86	-0.26	4.4
iShMBSETF	MBB	107.61	-0.02	0.7
iShMSCIACWIETF	ACWI	67.06	-0.07	13.3

ETF	Symbol	Closing Price	Chg (%)	YTD (%)
iShMSCIEAFE	EFA	66.37	-0.27	15.0
iShMSCIEAFESC	SCZ	59.29	...	19.0
iShMSCIEmgMarkets	EEM	43.76	0.50	25.8
iShMSCIEurozoneETF	EZU	41.23	-0.38	19.1
iShMSCIJapanETF	EWJ	54.25	-0.38	11.0
iShNasdaqBiotech	IBB	327.34	0.76	23.3
iShNatlMuniBdETF	MUB	110.44	0.01	1.6
iShRussell1000Gwth	IWF	122.64	0.30	16.9
iShRussell1000ETF	IWB	137.40	0.04	10.4
iShRussell1000Val	IWD	116.57	-0.14	4.1
iShRussell2000Gwth	IWO	172.75	0.47	12.2
iShRussell2000ETF	IWM	142.75	0.34	5.5
iShRussell2000Val	IWN	119.40	-0.04	0.4
iShRussell3000ETF	IWV	146.32	0.01	10.0
iShRussellMid-Cap	IWR	194.81	0.05	8.9
iShRussellMCValue	IWS	84.79	-0.07	3.4
iShS&PMC400Growth	IJK	200.57	0.40	11.1
iShS&P500Growth	IVW	141.23	0.04	16.0
iShS&P500ValueETF	IVE	105.72	-0.12	4.1
iShUSPfdStk	PFF	39.24	-0.05	5.6
iShTIPSBondETF	TIP	113.58	...	0.8
iSh1-3YTreasuryBd	SHY	84.55	-0.01	0.1
iSh7-10YTreasuryBd	IEF	107.07	-0.02	2.1
iSh20+YTreasuryBd	TLT	125.20	-0.26	5.1
iShRussellMCGrowth	IWP	116.20	0.31	13.2
PIMCOEnhShMaturity	MINT	101.73	-0.02	0.4
PwrShQQQ1	QQQ	144.72	0.44	22.2
PwrShS&P500LoVol	SPLV	45.30	-0.27	6.5
PwrShSrLoanPtf	BKLN	23.26	0.04	-0.4
SPDRBloombBarcHYBd	JNK	37.38	0.11	2.5
SPDR Gold	GLD	119.31	0.04	4.8
SchwabIntEquity	SCHF	32.65	-0.28	17.3
SchwabUS BrdMkt	SCHB	59.38	-0.03	10.2

ETF	Symbol	Closing Price	Chg (%)	YTD (%)
SchwabUS LC	SCHX	58.97	-0.02	10.7
SPDR DJIA Tr	DIA	215.09	-0.30	8.9
SPDR S&PMidCpTr	MDY	323.52	0.18	7.2
SPDR S&P 500	SPY	246.82	-0.02	10.4
SPDR S&P Div	SDY	89.00	-0.30	5.0
TechSelectSector	XLK	57.61	0.24	19.1
UtilitiesSelSector	XLU	52.79	-0.34	9.2
VanEckGoldMiner	GDX	22.80	-0.41	9.1
VangdInfoTech	VGT	148.87	0.40	22.5
VangdSCVal	VBR	124.42	...	3.2
VangdDivApp	VIG	93.45	-0.03	9.2
VangdFTSEDevMk	VEA	42.74	-0.19	15.4
VangdFTSE EM	VWO	42.76	0.50	24.5
VangdFTSE Europe	VGK	56.17	-0.37	17.2
VangdFTSEAWxUS	VEU	51.43	-0.05	16.3
VangdGrowth	VUG	131.13	0.31	17.7
VangdHlthCr	VHT	150.78	0.13	23.9
VangdHiDiv	VYM	78.90	-0.29	4.2
VangdIntermBd	BIV	84.92	-0.16	2.2
VangdIntrCorpBd	VCIT	88.17	-0.10	2.8
VangdLC	VV	113.14	-0.07	10.7
VangdMC	VO	145.63	0.05	10.6
VangdMC Val	VOE	103.75	-0.07	7.8
VangdREIT	VNQ	85.59	-0.19	1.3
VangdS&P500	VOO	226.60	-0.04	10.4
VangdST Bond	BSV	79.94	-0.06	0.6
VangdSTCpBd	VCSH	80.19	-0.05	1.0
VangdSC	VB	138.13	0.01	7.1
VangdTotalBd	BND	81.86	-0.05	1.6
VangdTotIntlBd	BNDX	54.44	-0.09	0.3
VangdTotIntlStk	VXUS	53.47	...	16.6
VangdTotalStk	VTI	125.96	0.01	10.1
VangdTotWrld	VT	69.16	...	15.4
VangdValue	VTV	97.54	-0.15	4.9
WisdTrEuropeHdg	HEDJ	62.42	-0.03	8.7
WisdTrJapanHdg	DXJ	52.23	-0.17	5.4

Declaration of Publication

I, Dominic Campodonico, as Senior Project Manager, Legal Notification Services at Gilardi & Co. LLC, a KCC Class Action Services Company in San Rafael, California, hereby certify that I caused the attached notice to be published as a press release by the following wire service:

Name of Publication:	BusinessWire
Address:	101 California Street 20th Floor
City, State, Zip	San Francisco, CA 94111
Phone #:	415-986-4422
State of:	California

The press release was distributed on July 25, 2017 to the following media circuits offered by the above-referenced wire service:

1. US1 National Newsline

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 28th day of September 2017, at San Rafael, California.

Dominic Campodonico

Business Wire
A Berkshire Hathaway Company

Robbins Geller Rudman & Dowd LLP and Motley Rice LLC Announce Proposed Settlement of Aegerion Securities Litigation

July 25, 2017 11:30 AM Eastern Daylight Time

BOSTON--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP and Motley Rice LLC regarding the Aegerion Securities Litigation:

If you bought Aegerion Pharmaceuticals, Inc. stock between April 30, 2013 and May 11, 2016, you could get a payment from a class action settlement.

A settlement has been proposed in a class action lawsuit captioned *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 14-cv-10105-MLW, concerning the price of Aegerion Pharmaceuticals, Inc. stock. The settlement will provide $22.25 million to pay claims from Aegerion investors who bought or acquired the company's stock from April 30, 2013, through and including May 11, 2016. If you qualify, you may send in a claim form to get benefits, or you can exclude yourself from the settlement, or you can object to it.

A hearing will be held on November 30, 2017, at 2:00 p.m. ET, before the Honorable Mark L. Wolf, at the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210, to consider whether to approve the settlement and a request by the lawyers representing all Class Members for an award of attorneys' fees of 25% of the $22.25 million settlement amount, plus expenses not to exceed $250,000, and a request by each of the Lead Plaintiffs for reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate.

If you purchased or acquired Aegerion publicly traded common stock between April 30, 2013 and May 11, 2016, inclusive, your rights may be affected by this Litigation and the settlement thereof. If you have not received a detailed Notice of Proposed Settlement of Class Action and a copy of the Proof of Claim and Release form, you may obtain copies by writing to *Aegerion Securities Litigation*, Claims Administrator, c/o Gilardi & Co. LLC, P.O. Box 30253, College Station, TX 77842-3253 or by downloading this information at www.aegerionsecuritieslitigation.com. You may also review the Stipulation of Settlement and all other settlement-related documents at www.aegerionsecuritieslitigation.com, or you may contact the Claims Administrator at 1-844-319-2120 for further information regarding the Settlement. You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

If you are a Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release online at www.aegerionsecuritieslitigation.com by November 17, 2017, or postmarked no later than November 17, 2017, establishing that you are entitled to a recovery. You will be

bound by any judgment rendered in the Litigation unless you request to be excluded, in writing, to *Aegerion Securities Litigation*, Claims Administrator, EXCLUSIONS, c/o Gilardi & Co. LLC, 3301 Kerner Blvd., San Rafael, CA 94901, postmarked by October 31, 2017.

Any objection to any aspect of the settlement must be filed with the Clerk of the Court on or before October 31, 2017, and also delivered by hand or first-class mail to:

ROBBINS GELLER RUDMAN
& DOWD LLP
ELLEN GUSIKOFF STEWART
655 West Broadway, Suite 1900
San Diego, CA 92101
1-800-449-4900

ROPES & GRAY LLP
RANDALL W. BODNER
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600
1-617-951-7000

The Court has retained the discretion to alter any of the deadlines or requirements outlined above for good cause shown.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE.

DATED: June 29, 2017

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

Contacts

Robbins Geller Rudman & Dowd LLP
Shareholder Relations
Rick Nelson
1-800-449-4900
or
Motley Rice LLC
Gregg S. Levin
Christopher F. Moriarty
1-843-216-9000

EXHIBIT E

AXG-EXCL00001 *AXG-EXCL00001*

[redacted]



Exclusion Cover Page

Case Name: Aegerion Pharmaceuticals, INC.

Case Code: AXG

Exclusion Deadline: October 31, 2017 (Postmark Date)

Name of Person Filing Exclusion: **American Beverage Association**

AMERICAN BEVERAGE ASSOCIATION

Aegerion Securities Litigation
Claims Administrator
EXCLUSIONS
c/o ~~Gilardi~~ & Co., LLC
3301 Kerner Blvd.
San Rafael, CA 94901

Re: KBC Asset Management NV, et al. v Aegerion Pharmaceuticals, Inc., et al.
No. 1:14-cv-10105-MLW

Dear Sir or Madam:

The United States District Court for the District of Massachusetts has advised the American Beverage Association ("ABA") that ABA is a potential class member in the securities class action captioned KBC Asset Management NV, et al. v Aegerion Pharmaceuticals, Inc., et al. ABA requests that it be excluded as a member of the class and, pursuant to the Court notice, is providing the following information regarding ABA's purchase and sale of Aegerion Pharmaceuticals common stock between the period of April 30, 2013 and May 11, 2016:

▪ July 30, 2013	Purchased 651 shares	Total Purchase Price	$55,370.69
▪ Sept. 3, 2013	Sold 325 shares	Total Sale Price	$28,049.34
▪ Sept. 23, 2013	Sold 326 shares	Total Sale Price	$26,809.11

Should you require additional information, please feel free to contact me at the address below or at [redacted]

Sincerely,

Amy Hancock

Amy Hancock
Executive Vice President/
General Counsel

[redacted]

Dear Recipient:

You have been identified as a potential class member in a securities class action involving Aegerion Pharmaceuticals, Inc. captioned *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 1:14-cv-10105-MLW. Enclosed is a notice about the settlement of that class action lawsuit. You may be eligible to claim a payment from the settlement or you may want to act on other legal rights. Important facts are highlighted below and explained in the notice:

- **Security:** Aegerion Pharmaceuticals, Inc. common stock.
- **Time Period:** Aegerion Pharmaceuticals, Inc. stock bought from April 30, 2013 through and including May 11, 2016.
- **Settlement Amount:** $22.25 million (the average distribution will be $0.31 per share if claims are ~~submitted for each share, before deductions for costs and attorneys' fees~~).
- **Reasons for Settlement:** Avoids costs and risks from continuing the lawsuit; avoids risks resulting from the present weak financial condition of Aegerion and the limited resources with which a settlement or judgment could be paid; releases defendants from liability.
- **If the Case had not Settled:** There would have been further litigation and possibly a trial. Plaintiffs estimated that they may have obtained a judgment as high as $844.6 million, but acknowledge they may not have been able to collect on that judgment. The defendants think that plaintiffs would not have won anything from a trial.
- **Attorneys' Fees and Expenses:** Counsel for the Class will ask the Court for an award of attorneys' fees of 25% of the Settlement Amount, plus expenses not to exceed $250,000. Each of the Class Representatives will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately $0.08 per share of Aegerion common stock included in the Class Period.
- **Deadlines:**
  - **Claims:** November 17, 2017
  - **Exclusions:** October 31, 2017
  - **Objections:** October 31, 2017
  - **Court Hearing on Fairness of Settlement:** November 30, 2017, at 2:00 p.m. ET
- **More Information:** You may contact the Claims Administrator toll-free at 1-844-319-2120, or visit www.aegerionsecuritieslitigation.com. You may also contact representatives of counsel for the Class:

Rick Nelson, Shareholder Relations
Robbins Geller Rudman & Dowd LLP
655 West Broadway, Suite 1900
San Diego, CA 92101
1-800-449-4900

Gregg S. Levin, Christopher F. Moriarty
Motley Rice LLC
28 Bridgeside Blvd.
Mt. Pleasant, SC 29464
1-843-216-9000

Get more details in the enclosed Notice from the United States District Court for the District of Massachusetts.

TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF AEGERION PHARMACEUTICALS, INC. ("AEGERION" OR THE "COMPANY") DURING THE PERIOD FROM APRIL 30, 2013 THROUGH AND INCLUDING MAY 11, 2016 (THE "CLASS PERIOD")

A FEDERAL COURT AUTHORIZED THIS NOTICE. THIS IS NOT A SOLICITATION FROM A LAWYER.

THE COURT HAS RETAINED THE DISCRETION TO ALTER ANY OF THE DEADLINES AND REQUIREMENTS SET FORTH HEREIN FOR GOOD CAUSE SHOWN.

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS ACTION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THE SETTLEMENT PROCEEDS, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE FORM ("PROOF OF CLAIM") **POSTMARKED (IF MAILED) OR RECEIVED (IF SUBMITTED ONLINE) ON OR BEFORE NOVEMBER 17, 2017.**

The purpose of this Notice is to inform you of (i) the pendency of this class action (the "Litigation") between Lead Plaintiffs KBC Asset Management NV, Sheet Metal Workers' National Pension Fund, and Chester County Employees' Retirement Fund ("Lead Plaintiffs") and Defendants Aegerion, Marc D. Beer, Craig Fraser, and Mark J. Fitzpatrick ("Defendants"); (ii) the proposed $22.25 million settlement reached therein (the "Settlement"); and (iii) the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and Lead Counsel's application for fees, costs, and expenses (which will include Lead Plaintiffs' reimbursement for their time and expenses representing the Class). This Notice describes what steps you may take in relation to the Settlement and this class action.[1]

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A PROOF OF CLAIM FORM	The only way to be eligible to receive a payment from the Settlement. Unless otherwise extended by the Court, **Proof of Claim forms must be postmarked (if mailed) or received (if submitted online) on or before November 17, 2017.**
EXCLUDE YOURSELF	Get no payment. This is the only option that ***potentially*** allows you to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement. Unless otherwise extended by the Court, **exclusions must be postmarked on or before October 31, 2017.**
OBJECT	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys' fees and expenses. You will still be a Member of the Class. Unless otherwise extended by the Court, **objections must be *received* by the Court and counsel for the Settling Parties on or before October 31, 2017.**
GO TO THE HEARING ON NOVEMBER 30, 2017 AT 2:00 P.M. ET	Ask to speak in Court about the fairness of the Settlement. Unless otherwise extended by the Court, **requests to speak must be *received* by the Court and counsel for the Settling Parties on or before October 31, 2017.**
DO NOTHING	Receive no payment. You will, however, still be a Member of the Class, which means that you give up your right to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement and you will be bound by any judgments or orders entered by the Court in the Litigation.

SUMMARY OF THIS NOTICE

The Nature of this Lawsuit

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the "Court"). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and omissions of information necessary for investors to understand that JUXTAPID was not performing and could not

[1] All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation of Settlement dated January 17, 2017 (the "Stipulation"), which is available on the website www.aegerionsecuritieslitigation.com.

lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

Statement of Class Recovery

Pursuant to the Settlement described herein, a $22.25 million settlement fund has been established. Based on Lead Plaintiffs' estimate of the number of shares of Aegerion common stock damaged during the Class Period, the average distribution per share under the Plan of Allocation is roughly $0.31 per share before deduction of any taxes on the income earned on the Settlement Amount, notice and administration costs, and allowable attorneys' fees and expenses as determined by the Court. **These are only estimates, however.** A Class Member's actual recovery will be a proportion of the Net Settlement Fund determined by that claimant's claims as compared to the total claims of all Class Members who submit acceptable Proofs of Claim. An individual Class Member may receive more or less than this estimated average amount, depending on the number of claims submitted, when during the Class Period a Class Member purchased or acquired Aegerion common stock, the purchase price paid, and whether those shares were held at the end of the Class Period or sold during the Class Period, and, if sold, when they were sold and the amount received. *See* Plan of Allocation set forth and discussed at pages 9-11 below for more information on the calculation of your claim.

Statement of Potential Outcome of Case

The Settling Parties disagree on both liability and damages and do not agree on the amount of damages that would be recoverable if the Class prevailed on each claim alleged. Defendants deny that they are liable to the Class and deny that the Class has suffered any damages. The issues on which the parties disagree are many, but include: (1) whether Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws, or any other laws; (2) whether Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (4) the amount, if any, by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (5) the effect of various market forces on the price of Aegerion common stock at various times during the Class Period; (6) the extent to which external factors influenced the price of Aegerion common stock at various times during the Class Period; (7) the extent to which the various matters that Lead Plaintiffs alleged were materially false or misleading influenced (if at all) the price of Aegerion common stock at various times during the Class Period; and (8) the extent to which the various allegedly adverse material facts that Lead Plaintiffs alleged were omitted influenced (if at all) the price of Aegerion common stock at various times during the Class Period. A consultant retained by counsel for Plaintiffs has opined that, if Lead Plaintiffs prevailed on all of their claims, recoverable damages could be as high as $844.6 million, an amount which Defendants dispute.

Reasons for the Settlement

Lead Plaintiffs' principal reason for entering into the Settlement is the benefit to the Class now, without further risk or the delays inherent in continued litigation. The cash benefit under the Settlement must be considered against the significant risk that a smaller recovery – or, indeed, no recovery at all – might be achieved after contested motions, trial, and likely appeals, a process that could last several years into the future. Those risks include the present financial condition of Aegerion, the limited insurance proceeds, the resources of the Individual Defendants, and Aegerion's financial obligations under its Settlement Agreement with the U.S. Department of Justice and the U.S. Securities and Exchange Commission. Lead Plaintiffs have therefore concluded that the proposed Settlement is fair, reasonable and adequate to Members of the Class. On November 29, 2016, Aegerion and QLT Inc. ("QLT") merged, with Aegerion becoming an indirect wholly owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc. ("Novelion"). Under the terms of the merger, however, Novelion is not responsible for any liability of Defendants to the Class, and the Class cannot access any of Novelion's assets.

Moreover, at the time of entering into the Settlement, Aegerion's prospects for continuing as a going concern were questioned by its outsider auditor, Ernst & Young LLP ("E&Y"). *See* Aegerion Pharms., Inc., Quarterly Report (Form 10-Q) (Aug. 9, 2016) at 96 (noting E&Y's "substantial doubt" about Aegerion's ability to continue as a going concern in its report for year-end 2015). If Aegerion were to enter bankruptcy, the Class would only have a remote chance of eventually obtaining any recovery. In this regard, from December 31, 2015 to June 30, 2016, Aegerion's available cash fell from $64 million to $46 million. *Id.* at 4. Aegerion's financial situation was such that it needed to arrange a $15 million "lifeline" loan with QLT. Absent such a loan, Aegerion stated that it "would need to raise capital or obtain alternative financing to . . . fund our operations," or it would be forced to "delay, reduce or cease operations." *Id.* at 109. Aegerion also projected that it would have a negative net income of $130 million in 2016 and a negative net income of $53 million in 2017. *See* QLT Inc., Registration Statement (Form S-4) (Aug. 8, 2016) at 80.

Further depleting the available resources available to the Class, Aegerion carries substantial debts and obligations, including $325 million in convertible notes that come due in 2019 and $40 million payable over three years

to the U.S. Department of Justice and the U.S. Securities and Exchange Commission as part of the resolution of certain investigations that had been conducted by those agencies.

Finally, the insurance proceeds available to cover the claims in this Litigation are limited, further reducing the amount available to the Class. The longer the litigation continued, the more the available insurance proceeds would have been reduced, including the possibility that all available insurance policies would have been exhausted before any verdict or later settlement.

For Defendants, who have denied and continue to deny all allegations of liability, fault, or wrongdoing whatsoever in connection with this matter, the principal reason for entering into the Settlement is to eliminate the uncertainty, risk, costs, and burdens inherent in any litigation, especially in complex cases such as this action. Defendants have concluded that further litigation could be protracted and distracting.

Under these circumstances, and given the complex and highly uncertain nature of proceeding with the action and eventually trying this case before a jury, Lead Plaintiffs submit that the resolution of the Litigation for $22,250,000 is an excellent result for the Class.

Statement of Attorneys' Fees and Expenses Sought

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount, plus expenses not to exceed $250,000, plus interest earned on both amounts at the same rate as earned by the Settlement Fund. Since the Litigation's inception, Lead Plaintiffs' Counsel have expended considerable time and effort in the prosecution of this Litigation on a wholly contingent basis and have advanced the expenses of the Litigation in the expectation that if they were successful in obtaining a recovery for the Class, they would be paid from such recovery. In addition, as part of that application, each of the Lead Plaintiffs will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately $0.08 per allegedly damaged share of Aegerion common stock.

Further Information

For further information regarding the Litigation, this Notice or to review the Stipulation, please contact the Claims Administrator toll-free at 1-844-319-2120, or visit the website www.aegerionsecuritieslitigation.com. Additionally, documents related to the Settlement and this case will be posted on the website.

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, www.rgrdlaw.com or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

Please Do Not Call the Court or Defendants with Questions About the Settlement.

BASIC INFORMATION

1. Why did I get this notice package?

This Notice was sent to you pursuant to an Order of a U.S. Federal Court because you or someone in your family or an investment account for which you serve as custodian may have purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016 ("Class Period").

This Notice explains the class action lawsuit, the Settlement, Class Members' legal rights in connection with the Settlement, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of the Litigation is the United States District Court for the District of Massachusetts, and the case is known as *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, Case No. 1:14-cv-10105-MLW. The case has been assigned to the Honorable Mark L. Wolf. The parties representing the Class are the "Lead Plaintiffs," and the company and individuals they sued and who have now settled are called the Defendants.

2. What is this lawsuit about?

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the "Court"). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and

omissions of information necessary for investors to understand that JUXTAPID was not performing and could not lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

On June 1, 2015, Lead Plaintiffs filed their Amended Class Action Complaint ("Amended Complaint"). On July 31, 2015, Defendants filed their Motion to Dismiss the Amended Complaint. On August 21, 2015, Lead Plaintiffs filed their Second Amended Class Action Complaint ("Second Amended Complaint"). Defendants, on September 4, 2015, moved to strike the Second Amended Complaint. Lead Plaintiffs filed their opposition to the Motion to Strike on September 18, 2015.

Following oral argument on Defendants' Motion to Strike the Second Amended Complaint and Lead Plaintiffs' Motion for Leave to File the Second Amended Complaint, the Court entered an order requiring the parties to, among other things, confer and "report whether they have reached an agreement to permit or withdraw the lead plaintiffs' Second Amended Complaint." The parties thereafter conferred but were unable to reach an agreement, and informed the Court that Lead Plaintiffs would file an opposition to the Motion to Dismiss the Amended Complaint.

Following Aegerion's May 12, 2016 announcement that it had reached preliminary agreements in principle with the U.S. Department of Justice and the staff of the U.S. Securities and Exchange Commission regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID, the parties conferred and reached an agreement for Lead Plaintiffs to file their Third Amended Class Action Complaint ("Third Amended Complaint"), which would extend the putative Class Period to April 30, 2013 through May 11, 2016, inclusive. Lead Plaintiffs filed the Third Amended Complaint on June 27, 2016.

In an effort to conserve judicial recovery and attempt to settle the Litigation, the parties engaged the services of the Hon. Daniel Weinstein (Ret.) and Jed Melnick, Esq. of JAMS, nationally recognized mediators. The parties prepared detailed mediation statements and engaged in a full-day in-person mediation session on November 14, 2016. These efforts culminated with the parties agreeing on November 29, 2016, to settle the Litigation for $22,250,000, subject to the negotiation of the terms of a Stipulation of Settlement and approval by the Court.

3. Why is there a settlement?

The Court has not decided in favor of Defendants or in favor of Lead Plaintiffs. Instead, both sides agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and Lead Plaintiffs agreed to the Settlement in order to ensure that Class Members will receive compensation, particularly in light of Aegerion's precarious financial condition and the limited resources of the Defendants.

WHO IS IN THE SETTLEMENT

4. How do I know if I am a Member of the Class?

The Court directed that everyone who fits this description is a Class Member: ***all Persons who purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016***, except those Persons and entities that are excluded.

Excluded from the Class are: Defendants, the officers and directors of Aegerion during the Class Period, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which Defendants have or had a controlling interest. Also excluded from the Class is any Class Member who timely and validly excludes themselves therefrom by submitting a request for exclusion in accordance with the requirements set forth in question 11 below.

Please Note: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive a payment from the Settlement. If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit the Proof of Claim that is being distributed with this Notice and the required supporting documentation as set forth therein postmarked or submitted online on or before November 17, 2017.

5. What if I am still not sure if I am included?

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at 1-844-319-2120, or you can fill out and return the Proof of Claim form enclosed with this Notice package, to see if you qualify.

THE SETTLEMENT BENEFITS – WHAT YOU GET

6. What does the Settlement provide?

The Settlement provides that, in exchange for the release of the Released Claims (defined below) and dismissal of the Litigation, Defendants have agreed to pay (or cause to be paid) $22.25 million in cash to be distributed

after taxes, fees, and expenses, *pro rata*, to Class Members who send in or submit a valid Proof of Claim form pursuant to the Court-approved Plan of Allocation. The Plan of Allocation is described in more detail at the end of this Notice.

7. How much will my payment be?

Your share of the Net Settlement Fund will depend on several things, including the total amount of claims represented by the valid Proof of Claim forms that Class Members send in or submit, compared to the amount of your claim, all as calculated under the Plan of Allocation discussed below.

HOW YOU GET A PAYMENT – SUBMITTING A CLAIM FORM

8. How can I get a payment?

To be eligible to receive a payment from the Settlement, you must submit a Proof of Claim form. A Proof of Claim form is enclosed with this Notice or it may be downloaded at www.aegerionsecuritieslitigation.com. Read the instructions carefully, fill out the Proof of Claim, include all the documents the form asks for, sign it, and **mail or submit it online so that it is postmarked (if mailed) or received (if submitted online) no later than November 17, 2017.** The Proof of Claim form may be submitted online at www.aegerionsecuritieslitigation.com.

9. When would I get my payment?

The Court will hold a Settlement Hearing on November 30, 2017, at 2:00 p.m. ET, to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals. It is always uncertain whether appeals can be resolved, and if so, how long it would take to resolve them. It also takes time for all the Proofs of Claim to be processed. Please be patient.

10. What am I giving up to get a payment or to stay in the Class?

Unless you timely and validly exclude yourself, you are staying in the Class, and that means you cannot sue, continue to sue, or be part of any other lawsuit against Defendants or their Related Parties about the Released Claims (as defined below) in this case. It also means that all of the Court's orders will apply to you and legally bind you. If you remain a Class Member, and if the Settlement is approved, you will give up all "Released Claims" (as defined below), including "Unknown Claims" (as defined below), against the "Released Persons" (as defined below):

- "Released Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, whether class or individual in nature, whether direct or derivative, whether fixed or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, which arise out of or relate in any way to both: (i) the purchase or acquisition of shares of Aegerion publicly traded common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were or could have been alleged by Lead Plaintiffs or any Class Member in the Litigation. "Released Claims" does not include claims to enforce the Settlement. "Released Claims" includes "Unknown Claims" as defined below.
- "Released Defendants' Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments, and causes of action of every nature and description (including Unknown Claims), whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, that arise out of or relate in any way to the institution, prosecution or settlement of the claims against Defendants in the Litigation, except for claims relating to the enforcement of the Settlement.
- "Released Persons" means each and all of the Defendants and their Related Parties.
- "Related Parties" means each of a Defendant's respective former, present or future parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, attorneys, advisors, accountants, auditors, and insurers and reinsurers of each of them; and the predecessors, successors, estates, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives and assigns of each of them, in their capacity as such.
- "Unknown Claims" means any and all Released Claims or Released Defendants' Claims that any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class

Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or to the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members. With respect to any and all Released Claims and Released Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

> **A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but the Settling Parties shall expressly settle and release, and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

EXCLUDING YOURSELF FROM THE CLASS

If you do not want to participate in this Settlement, and you want to keep the right to potentially sue the Defendants and the other Released Persons, on your own, about the claims being released by the Settlement, then you must take steps to remove yourself from the Class. This is called excluding yourself – or is sometimes referred to as "opting out."

11. How do I opt out of the Class and the proposed Settlement?

To exclude yourself from the Class and the Settlement, you must send a letter by First-Class Mail stating that you "request exclusion from the Class in the *Aegerion Securities Litigation*." You ***cannot*** exclude yourself by telephone or e-mail. Your letter must include your purchases, acquisitions, and sales of Aegerion publicly traded common stock during the Class Period, including the dates, the number of shares of Aegerion publicly traded common stock you purchased, acquired, or sold, and price paid or received for each such purchase, acquisition, or sale. In addition, you must include your name, address, telephone number, and your signature. Unless otherwise extended by the Court, you must submit your exclusion request so that it is **postmarked no later than October 31, 2017** to:

Aegerion Securities Litigation
Claims Administrator
EXCLUSIONS
c/o Gilardi & Co. LLC
3301 Kerner Blvd.
San Rafael, CA 94901

Unless otherwise altered by Order of the Court, your exclusion request must comply with the above requirements in order to be valid. If you ask to be excluded, you will not receive any payment from the Settlement, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue the Defendants and the other Released Persons about the Released Claims in the future.

12. If I do not exclude myself, can I sue the Defendants and the other Released Persons for the same thing later?

No. Unless you exclude yourself, you give up any rights you may potentially have to sue the Defendants and the other Released Persons for any and all Released Claims. If you have a pending lawsuit against the Released Persons, speak to your lawyer in that case immediately. You must exclude yourself from the Class in this Litigation to continue your own lawsuit. Remember, the exclusion deadline is October 31, 2017.

13. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you should not send in a Proof of Claim to ask for any money. But, if you do exclude yourself, you may have the right to potentially sue or be part of a different lawsuit against the Defendants and the other Released Persons.

THE LAWYERS REPRESENTING YOU

14. Do I have a lawyer in this case?

The Court ordered that the law firms of Robbins Geller Rudman & Dowd LLP and Motley Rice LLC represent the Class Members, including you. These lawyers are called Lead Counsel. If you want to be represented by your own lawyer, you may hire one at your own expense.

15. How will the lawyers be paid?

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount and for expenses and costs in an amount not to exceed $250,000 in connection with the Litigation, plus interest on such fees and expenses at the same rate as earned by the Settlement Fund. In addition, one or more of the Lead Plaintiffs will seek reimbursement for their time and expenses incurred in representing the Class in an amount not to exceed $17,500 in the aggregate. Such sums as may be approved by the Court will be paid from the Settlement Fund.

OBJECTING TO THE SETTLEMENT

You can tell the Court that you do not agree with the Settlement or any part of it.

16. How do I tell the Court that I object to the proposed Settlement?

If you are a Class Member, you can comment or object to the proposed Settlement, the proposed Plan of Allocation, Lead Counsel's fee and expense application, and/or Lead Plaintiffs' time and expense request. You can write to the Court setting out your comment or objection. The Court will consider your views. To comment or object, you must send a signed letter saying that you wish to comment on or object to the proposed Settlement in the *Aegerion Securities Litigation*. Include your name, address, daytime telephone number, e-mail address, and your signature, identify the date(s), price(s), and number(s) of shares of Aegerion publicly traded common stock you purchased, acquired, and sold during the Class Period, and state your comments or the reasons why you object to the proposed Settlement, Plan of Allocation and/or fee and expense application. You must also include copies of documents demonstrating such purchase(s), acquisition(s) and/or sale(s). Unless otherwise extended by Order of the Court, your comments or objection must be filed with the Court and mailed or delivered to each of the following addresses such that it is ***received*** **no later than October 31, 2017:**

COURT	**LEAD COUNSEL**	**DEFENDANTS' COUNSEL**
U.S. DISTRICT COURT DISTRICT OF MASS. John Joseph Moakley U.S. Courthouse 1 Courthouse Way, Suite 2300 Boston, MA 02210	Ellen Gusikoff Stewart ROBBINS GELLER RUDMAN & DOWD LLP 655 West Broadway Suite 1900 San Diego, CA 92101	Randall W. Bodner ROPES & GRAY LLP Prudential Tower 800 Boylston Street Boston, MA 02199-3600

17. What is the difference between objecting and excluding?

Objecting is simply telling the Court that you do not like something about the Settlement. You can object **only** if you stay in the Class.

Excluding yourself is telling the Court that you do not want to be paid and do not want to release any claims you think you may have against Defendants and their Related Parties. If you exclude yourself, you cannot object to the Settlement because it does not affect you.

THE COURT'S SETTLEMENT HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement. You may attend and you may ask to speak, but you do not have to.

18. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Settlement Hearing at **2:00 p.m. ET, on November 30, 2017**, in the Courtroom of the Honorable Mark L. Wolf, at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210. At the hearing, the Court will consider whether the Settlement and the Plan of Allocation are fair, reasonable, and adequate. If there are objections, the Court will consider them, even if you do not ask to speak at the hearing. The Court will listen to people who attend the hearing. The Court may also issue a ruling on Lead Counsel's application for attorneys' fees and expenses (which request will include an application for reimbursement for Lead Plaintiffs' time and expenses in representing the Class in an amount not to exceed $17,500 in the aggregate). After the Settlement Hearing, the Court will decide whether to approve the Settlement and the Plan of Allocation. We do not know how long these decisions will take. You should be aware that the Court may change the date and time of the Settlement Hearing without another notice being sent to Class Members. If you want to attend the hearing, you should check with Lead Counsel or the Settlement website www.aegerionsecuritieslitigation.com beforehand to be sure that the date and/or time has not changed.

19. Do I have to come to the hearing?

No. Lead Counsel will answer questions the Court may have. But, you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but that is not necessary. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

20. May I speak at the hearing?

If you object to the Settlement, the Plan of Allocation, or the fee and expense application, you may ask the Court for permission to speak at the Settlement Hearing. To do so, you must include with your objection (*see* question 16 above) a statement saying that it is your "Notice of Intention to Appear in the *Aegerion Securities Litigation*." Persons who intend to object to the Settlement, the Plan of Allocation, and/or any attorneys' fees and expenses to be awarded to Lead Counsel (including any reimbursement to Lead Plaintiffs for their time and expenses representing the Class) and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Settlement Hearing. Unless otherwise extended by an Order of the Court, your notice of intention to appear must be **received** no later than October 31, 2017, and addressed to the Clerk of Court, Lead Counsel, and Defendants' counsel, at the addresses listed above in question 16.

You cannot speak at the hearing if you exclude yourself from the Class.

IF YOU DO NOTHING

21. What happens if I do nothing?

If you do nothing, you will not receive any money from this Settlement. In addition, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants and their Related Parties about the Released Claims in this case.

GETTING MORE INFORMATION

22. How do I get more information?

For even more detailed information concerning the matters involved in this Litigation, you can obtain answers to common questions regarding the proposed Settlement by contacting the Claims Administrator toll-free at 1-844-319-2120. Reference is also made to the Stipulation, to the pleadings in support of the Settlement, to the Orders entered by the Court, and to the other settlement-related papers filed in the Litigation, which are posted on the Settlement website at www.aegerionsecuritieslitigation.com, and which may be inspected at the Office of the Clerk of the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Suite 2300, Boston, MA 02210, during regular business hours. For a fee, all papers filed in this Litigation are available at www.pacer.gov.

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, www.rgrdlaw.com or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG CLASS MEMBERS

The Settlement Amount of $22.25 million and any interest earned thereon is the "Settlement Fund." The Settlement Fund, less all taxes, approved costs, fees, and expenses (the "Net Settlement Fund") shall be distributed to Class Members who submit timely and valid Proof of Claim forms to the Claims Administrator ("Authorized Claimants"). The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have an overall net loss on all of your transactions in Aegerion publicly traded common stock during the Class Period.

For purposes of formulating the Plan of Allocation and determining the amount an Authorized Claimant may recover under it, Lead Counsel have conferred with their damages consultant regarding the Plan of Allocation and it reflects an assessment of the damages that they believe could have been recovered by Class Members had Lead Plaintiffs prevailed at trial.

In the unlikely event there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's claim, as defined below. If, however, and as is more likely, the amount in the Net Settlement Fund is not sufficient to permit payment of the total claim of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's claim bears to the total of the claims of all Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants. Allowed claims will also be subjected to the statutory 90-day look-back amount provided for in the Private Securities Litigation Reform Act of 1995 ("PSLRA").[2]

The calculation of claims below is not an estimate of the amount you will receive. It is a formula for allocating the Net Settlement Fund among all Authorized Claimants. Furthermore, if any of the formulas set forth below yield an amount less than or equal to $0.00, the claim per share shall be $0.00.

A "claim" will be calculated as follows:

Aegerion Securities Litigation
CUSIP: 00767E102
April 30, 2013 – May 11, 2016

The Plan of Allocation is based on the following chart setting forth alleged inflation per share amounts for Class Period common stock purchases, acquisitions, and sales and also takes into account the mean trading price of Aegerion common stock during the PSLRA 90-day look-back period (which was $1.60).

Inflation Period	Alleged Inflation per Share
April 30, 2013 – January 9, 2014	$36.21
January 10, 2014 – May 6, 2014	$27.21
May 7, 2014 – October 30, 2014	$18.02
October 31, 2014 – July 5, 2015	$4.05
July 6, 2015 – November 9, 2015	$2.85
November 10, 2015 – May 11, 2016	$0.35
May 12, 2016 – thereafter	$0.00

For shares of Aegerion common stock ***purchased, or acquired, on or between April 30, 2013 through May 11, 2016***, the recovery per share shall be as follows:

a) If sold on or between April 30, 2013 through May 11, 2016, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition less the inflation per share at the time of sale; and (ii) the difference between the purchase or acquisition price and the selling price.

b) If retained beyond May 11, 2016 and sold on or before August 9, 2016, the recovery per share shall be the least of: (i) the inflation per share at the time of purchase or acquisition; (ii) the difference between the purchase or acquisition price and the selling price; and (iii) the difference between the purchase or acquisition price and the average closing price up to the date of sale as set forth in the table below.

[2] Pursuant to Section 21D(e)(1) of the PSLRA, "in any private action arising under this chapter in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market."

c) If retained at the close of trading on August 9, 2016, or sold thereafter, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition; and (ii) the difference between the purchase or acquisition price and $1.60.

Date	Closing Price	Average Closing Price
5/12/2016	$1.91	$1.91
5/13/2016	$1.73	$1.82
5/16/2016	$2.31	$1.98
5/17/2016	$1.89	$1.96
5/18/2016	$1.78	$1.92
5/19/2016	$1.67	$1.88
5/20/2016	$1.73	$1.86
5/23/2016	$1.64	$1.83
5/24/2016	$1.64	$1.81
5/25/2016	$1.61	$1.79
5/26/2016	$1.73	$1.79
5/27/2016	$1.82	$1.79
5/31/2016	$1.78	$1.79
6/1/2016	$1.93	$1.80
6/2/2016	$1.76	$1.80
6/3/2016	$1.71	$1.79
6/6/2016	$1.78	$1.79
6/7/2016	$1.68	$1.78
6/8/2016	$1.60	$1.77
6/9/2016	$1.50	$1.76
6/10/2016	$1.37	$1.74
6/13/2016	$1.26	$1.72
6/14/2016	$1.33	$1.70
6/15/2016	$1.71	$1.70
6/16/2016	$1.63	$1.70
6/17/2016	$1.69	$1.70
6/20/2016	$1.62	$1.70
6/21/2016	$1.53	$1.69
6/22/2016	$1.56	$1.69
6/23/2016	$1.67	$1.69
6/24/2016	$1.54	$1.68

Date	Closing Price	Average Closing Price
6/27/2016	$1.41	$1.67
6/28/2016	$1.47	$1.67
6/29/2016	$1.51	$1.66
6/30/2016	$1.49	$1.66
7/1/2016	$1.58	$1.65
7/5/2016	$1.47	$1.65
7/6/2016	$1.54	$1.65
7/7/2016	$1.65	$1.65
7/8/2016	$1.67	$1.65
7/11/2016	$1.62	$1.65
7/12/2016	$1.61	$1.65
7/13/2016	$1.58	$1.64
7/14/2016	$1.55	$1.64
7/15/2016	$1.51	$1.64
7/18/2016	$1.51	$1.64
7/19/2016	$1.48	$1.63
7/20/2016	$1.53	$1.63
7/21/2016	$1.49	$1.63
7/22/2016	$1.46	$1.62
7/25/2016	$1.47	$1.62
7/26/2016	$1.44	$1.62
7/27/2016	$1.55	$1.62
7/28/2016	$1.47	$1.61
7/29/2016	$1.44	$1.61
8/1/2016	$1.47	$1.61
8/2/2016	$1.44	$1.61
8/3/2016	$1.49	$1.60
8/4/2016	$1.51	$1.60
8/5/2016	$1.53	$1.60
8/8/2016	$1.54	$1.60
8/9/2016	$1.58	$1.60

The date of purchase or sale is the "contract" or "trade" date as distinguished from the "settlement" date. All purchase, acquisition, and sale prices shall exclude any fees and commissions. The receipt or grant by gift, devise or operation of law of Aegerion publicly traded common stock during the Class Period shall not be deemed a purchase or sale of Aegerion publicly traded common stock for the calculation of a claimant's recognized claim, nor shall it be deemed an assignment of any claim relating to the purchase of such shares unless specifically provided in the instrument of gift or assignment. The receipt of Aegerion publicly traded common stock during the Class Period in exchange for securities of any other corporation or entity shall not be deemed a purchase or sale of Aegerion publicly traded common stock.

For Class Members who held Aegerion publicly traded common stock at the beginning of the Class Period or made multiple purchases, acquisitions, or sales during the Class Period, the First-In, First-Out ("FIFO") method will be applied to such holdings, purchases, acquisitions, and sales for purposes of calculating a claim. Under the FIFO method, sales of Aegerion publicly traded common stock during the Class Period will be matched, in chronological order, first against shares of common stock held at the beginning of the Class Period. The remaining sales of common stock during the Class Period will then be matched, in chronological order, against common stock purchased or acquired during the Class Period.

A Class Member will be eligible to receive a distribution from the Net Settlement Fund only if a Class Member had a net overall loss, after all profits from transactions in all Aegerion common stock described above during the Class Period are subtracted from all losses. However, the proceeds from sales of common stock that have been matched against the common stock held at the beginning of the Class Period will not be used in the calculation of such net loss. No distributions will be made to Authorized Claimants who would otherwise receive a distribution of less than $10.00.

Payment pursuant to the Plan of Allocation set forth above shall be conclusive against all Authorized Claimants. Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability

whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. No Person shall have any claim against Lead Plaintiffs, Lead Plaintiffs' Counsel, the Claims Administrator, or other Person designated by Lead Counsel, Defendants, or Defendants' counsel based on distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. All Class Members who fail to complete and submit a valid and timely Proof of Claim shall be barred from participating in distributions from the Net Settlement Fund (unless otherwise ordered by the Court), but otherwise shall be bound by all of the terms of the Stipulation, including the terms of any judgment entered and the releases given.

Please contact the Claims Administrator or Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim. If you are unsatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class Members and the claims administration process, to decide the issue by submitting a written request.

Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. Lead Plaintiffs and Lead Plaintiffs' Counsel, likewise, will have no liability for their reasonable efforts to execute, administer, and distribute the Settlement.

Distributions will be made to Authorized Claimants after all claims have been processed and after the Court has finally approved the Settlement. If any funds remain in the Net Settlement Fund by reason of un-cashed distribution checks or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Class Members who are entitled to participate in the distribution of the Net Settlement Fund cash their distributions, any balance remaining in the Net Settlement Fund after at least six (6) months after the initial distribution of such funds shall be used: (a) first, to pay any amounts mistakenly omitted from the initial disbursement; (b) second, additional settlement administration fees, costs, and expenses, including those of Lead Plaintiffs' Counsel as may be approved by the Court; and (c) to make a second distribution to claimants who cashed their checks from the initial distribution and who would receive at least $10.00, after payment of the estimated costs, expenses, or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. These redistributions shall be repeated, if economically feasible, until the balance remaining in the Net Settlement Fund is *de minimis* and such remaining balance shall then be distributed to an appropriate non-sectarian, non-profit charitable organization serving the public interest selected by Lead Counsel and approved by the Court.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased or acquired Aegerion publicly traded common stock during the Class Period for the beneficial interest of an individual or organization other than yourself, the Court has directed that, WITHIN SEVEN (7) DAYS OF YOUR RECEIPT OF THIS NOTICE, you either (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or which you purchased or acquired such securities during such time period, or (b) request additional copies of this Notice and the Proof of Claim form, which will be provided to you free of charge, and within ten (10) days mail the Notice and Proof of Claim form directly to the beneficial owners of the securities referred to herein. If you choose to follow alternative procedure (b), upon such mailing, you must send a statement to the Claims Administrator confirming that the mailing was made as directed and retain the names and addresses for any future mailings to Class Members. You are entitled to reimbursement from the Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, including reimbursement of postage expense and the cost of ascertaining the names and addresses of beneficial owners. Your reasonable expenses will be paid upon request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator:

Aegerion Securities Litigation
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box 30253
College Station, TX 77842-3253
www.aegerionsecuritieslitigation.com

DATED: June 29, 2017

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

AMERICAN BEVERAGE ASSOCIATION

[redacted]

CAP DISTRICT
MD 207
29 AUG '17
PM 4 L

Hasler
08/29/2017
US POSTAGE $00.67²

AEGERION SECURITIES LITIGATION
CLAIMS ADMINISTRATOR
EXCUSIONS
C/O GILARDI & CO., LLC
3301 KERNER BLVD.
SAN RAFAEL, CA 94901

RECEIVED
SEP 01 2017
BY:

AXG

94901-489625